| Excerpt | Reference |
|---|
| "Most patients with esophageal cancer are relatively old and have often multiorgan dysfunction." | ( Hioki, K; Hiramatsu, Y; Kawaguchi, Y; Kojima, Y; Yamamoto, M; Yamanaka, H, 1991) |
| "The incidence of esophageal cancer is much higher in men than in women and the prognosis is generally worse in men than in women." | ( Hattori, T; Hirai, T; Kawano, K; Mukaida, H; Niimoto, M; Toge, T; Yamashita, Y, 1989) |
| "Esophageal cancer is a complex and multifactorial problem." | ( Chui, SX; Feng, L; Lu, SH; Luo, FJ; Montesano, R; Rajewsky, MF; Saffhill, R; Umbenhauer, D; Zhang, MS, 1986) |
| "The etiology of cancer of the esophagus is known to be complex and composed of multiple factors, those caused by the environment being of greatest importance." | ( Tollefson, L, 1985) |
| "Since esophageal cancer is an important cause of cancer deaths in many parts of the world, information as to factors which can enhance protective systems of this organ may be of value." | ( Chuan, J; Sparnins, VL; Wattenberg, LW, 1982) |
| "Patients with T4 esophageal cancer are expected to have long term survival from extended operations when their cancer have no distant metastasis, and no or minor regional lymph node metastasis, are resected completely by combined resection of invaded neighboring organs, and responders to preoperative chemo and/or radiotherapy." | ( Ayabe, H, 1997) |
| "Locally advanced esophageal cancer is rarely operable and has a dismal prognosis." | ( Ancona, E; Bonavina, L; Castoro, C; Chiarion-Sileni, V; Merigliano, S; Peracchia, A; Ruol, A; Santi, S, 1997) |
| "Squamous cell cancer of the esophagus is the most common cancer among black South African males, and 60% of patients present with localized inoperable disease." | ( Burger, W; Falkson, CI; Falkson, G; Nel, JS; Schoeman, L; Slabber, CF, 1998) |
| "Esophageal cancer is a major cause of morbidity and mortality worldwide." | ( Beauchamp, RD; Blanke, CD; Choy, H; Johnson, DH; Leach, S; Roberts, J; Teng, M; Washington, K, 1999) |
| "Oesophageal cancer is the fifth most frequent cause of cancer death world wide and most of these cancers occur in developing countries." | ( Hainaut, P; Montesano, R, 1998) |
| "Local control of esophageal cancer is excellent following neoadjuvant chemotherapy and radiation therapy." | ( Adelstein, DJ; Becker, M; Chidel, MA; Kupelian, PA; Rice, TW; Suh, JH, 1999) |
| "Esophageal cancer is the primary cause of malignant dysphagia, a major cause of morbidity and mortality." | ( Adler, DG; Baron, TH, 2001) |
| "Advanced esophageal cancers are highly malignant and frequently resistant to 5-fluorouracil (5-FU)." | ( Hamada, H; Ochiai, T; Shimada, H; Shimizu, T, 2001) |
| "Esophageal cancer is associated with the poorest prognosis among the digestive tract cancers, and chemotherapy is the treatment of choice for many patients." | ( Akiyama, S; Fujiwara, M; Hamada, H; Ito, K; Kasai, Y; Nakamura, H; Nakao, A; Sekiguchi, H, 2001) |
| "Esophageal cancer is treated optimally with a combined-modality approach according to most clinical investigators." | ( Jatoi, A; Thomas, CR, 2002) |
| "Esophageal cancer is a rare but highly virulent malignancy in the United States and Western Europe, and adenocarcinoma of the esophagus has had the most rapid rate of increase of any solid tumor malignancy." | ( Ilson, DH, 2002) |
| "Esophageal cancer is the most markedly increasing tumor entity in Western countries." | ( Barthel, B; Carayon, P; Faiss, S; Grabowski, P; Höpfner, M; Maaser, K; Scherübl, H; Sutter, AP; Zeitz, M, 2002) |
| "Since mucosal (T1a) esophageal cancer is well controlled by endoscopic treatment, chemoradiotherapy (CRTx) is not indicated." | ( Fujita, H; Hayabuchi, N; Matono, S; Sasahara, H; Shirouzu, K; Sueyoshi, S; Suzuki, G; Tanaka, T; Yamana, H, 2003) |
| "Esophageal cancer is an aggressive disease, and poor survival is achieved with surgery or chemoradiation therapy alone." | ( Anderson, SE; Bains, M; Ilson, DH; Kelsen, DP; Minsky, BD, 2003) |
| "Esophageal cancer is supposed to be more sensitive to chemotherapy compared to other gastrointestinal cancers." | ( Nabeya, Y; Ochiai, T, 2003) |
| "Esophageal cancer is one of the most lethal of all neoplasms." | ( Dehdashti, F; Siegel, BA, 2004) |
| "Esophageal cancer is a rare but highly virulent malignancy in the United States, and adenocarcinoma of the esophagus has had the most rapid rate of increase of any solid tumor malignancy." | ( Ilson, DH, 2004) |
| "Esophageal cancer is the ninth most common malignancy in the world and the seventh leading cause of death in American men." | ( Bubis, JA; Dragnev, KH; Rigas, JR, 2005) |
| "Esophageal cancer is a rare but highly virulent malignancy occurring in the United States and other Western countries." | ( Ilson, DH, 2004) |
| "Esophageal cancer is the sixth most common cause of cancer-related death worldwide." | ( Höpfner, M; Huether, A; Maaser, K; Scherübl, H; Sutter, AP, 2006) |
| "Esophageal cancers are highly lethal neoplasms which are generally refractory to conventional multidisciplinary interventions." | ( Nguyen, DM; Schrump, DS, 2005) |
| "Esophageal cancer is common worldwide, with poor prognosis." | ( Walle, T; Wen, X, 2007) |
| "Esophageal cancers are predominantly carcinomas, which are-due to their origin from the epithelial lining-visible by endoluminal view." | ( Brücher, BL; Sarbia, M; von Rahden, BH, 2006) |
| "Esophageal cancer is difficult to treat because of its rapid progression, and more effective therapeutic approaches are needed." | ( Fujisawa, T; Fujita, K; Ikeda, I; Masuda, T; Nakagama, H; Nakajima, A; Saitoh, S; Saubermann, LJ; Schaefer, K; Shimamura, T; Tachibana, M; Takahashi, H; Tomimoto, A; Wada, K; Yoneda, M; Yonemitsu, K, 2006) |
| "The incidence of esophageal cancer is markedly increased in patients with head and neck cancer, and the presence of esophageal cancer is associated with reduced survival rates." | ( Christoph, B; Grosse-Thie, W; Kloeppel, G; Middelberg-Bisping, C; Moschler, O; Mueller, MK; Spahn, TW, 2006) |
| "The stage of esophageal cancer is currently determined by the anatomic TNM classification system as opposed to information about tumor biology." | ( Bryant, AS; Cerfolio, RJ, 2006) |
| "Esophageal cancer is a substantial health problem because of its usually late stage at diagnosis and poor prognosis." | ( Cao, L; Jiang, Y; Liang, ZD; Wu, TT; Xu, XC; Zhang, H, 2007) |
| "The prognosis of esophageal cancer is not only affected by TNM stage but also by the level of serum vascular endothelial growth factor (S-VEGF)." | ( Cai, L; Cui, NJ; Liu, MZ; Wang, XS; Zhang, CQ, 2006) |
| "Esophageal cancer is multifactorial disease involving environmental and genetic risk factors." | ( Ghoshal, UC; Jain, M; Kumar, S; Lal, P; Mittal, B; Tiwari, A, 2007) |
| "Advanced gastroesophageal cancer is an incurable condition and more research is desirable." | ( Ajani, JA; Cen, P, 2007) |
| "Locally advanced esophageal cancer is challenging to treat." | ( Alberts, SR; Fitch, TR; Foster, NR; Jatoi, A; Lair, BS; Martenson, JA; McLeod, HL; Moore, DF; Nichols, F; Tschetter, LK, 2007) |
| "Esophageal cancer is one of the most common malignancies in the world." | ( Cai, Y; Du, XL; Feng, YB; Han, YL; Hu, H; Luo, ML; Shen, XM; Wang, MR; Xu, X; Zhang, Y, 2007) |
| "Cachexia in gastroesophageal cancers is associated with changes in APRP concentrations." | ( Blachut, K; Diakowska, D; Gamian, A; Grabowski, K; Krzystek-Korpacka, M; Kustrzeba-Wojcicka, I; Matusiewicz, M; Terlecki, G, 2008) |
| "Esophageal cancer is the sixth leading causes of cancer-related death in the world." | ( Cho, CH; Liu, X; Srivastava, G; Sung, JJ; Wu, WK; Yu, L; Zhang, ST, 2008) |
| "Esophageal cancer is the eighth most common cancer worldwide, and one of the most fatal diseases despite modern medical treatment." | ( Chang, JY; Chang, KY; Chao, J; Yen, Y, 2008) |
| "Esophageal cancer is one of the most aggressive cancers in the world." | ( Fujiwara, Y; Fukazawa, T; Hatakeyama, S; Motoki, T; Naomoto, Y; Nishikawa, T; Ohara, T; Omori, O; Sakurama, K; Shirakawa, Y; Takaoka, M; Tanabe, S; Tanaka, N; Wang, ZG; Watanabe, N; Yamatsuji, T, 2008) |
| "Accurate staging of esophageal cancer is important when determining which patients will potentially benefit from curative surgery." | ( Berry, H; Gananadha, S; Hazebroek, EJ; Leibman, S; Marx, G; Osgood, L; Pavlakis, N; Shon, IH; Smith, GS, 2008) |
| "Esophageal cancer is the third most common malignancy of the alimentary tract." | ( Alavi, A; Basu, S; Heidari, P; Salavati, A, 2009) |
| "Oesophageal cancer is on the rise and often present in an advanced state." | ( Chilton, AP; Das, D; Jankowski, JA, 2009) |
| "Esophageal cancer is the third most common gastrointestinal malignancy with a poor long-term survival and high mortality." | ( Gu, P; Huang, G; Pan, L; Wu, S; Xue, H, 2009) |
| "Esophageal cancer is a frequently fatal malignancy, and is described in certain regions in Northeast India with an incidence of esophageal squamous cell carcinoma many fold higher than the rest of the population." | ( Chattopadhyay, I; Hewitt, SM; Kapur, S; Mishra, A; Purkayastha, J; Saxena, S; Sharma, J; Singh, A, 2009) |
| "Esophageal cancer is the eighth most common malignancy, and one of the leading causes of cancer-related deaths worldwide." | ( Cheung, AL; Li, B; Li, YY; Tsao, SW, 2009) |
| "Oesophageal cancer is the sixth most common form of cancer death globally with almost 400,000 deaths annually." | ( Chandanos, E; Lagergren, J, 2009) |
| "Esophageal cancer is a relatively rare form of cancer, but some world areas have a markedly higher incidence than others: China, Iceland, India, Japan and United Kingdom, appear to have a higher incidence, as well as the region around the Caspian Sea." | ( Dikshit, R; Ganesh, B; Talole, SD, 2009) |
| "Esophageal cancer is one of the most frequently occurring cancers in the world." | ( Fujiwara, Y; Fukazawa, T; Hatakeyama, S; Motoki, T; Naomoto, Y; Nishikawa, T; Ohara, T; Omori, O; Sakurama, K; Shirakawa, Y; Takaoka, M; Tanabe, S; Tanaka, N; Wang, ZG; Watanabe, N; Yamatsuji, T, 2010) |
| "Oesophageal cancer is an aggressive disease and the optimal therapy for patients with resectable tumours remains unclear." | ( Malthaner, R; Spithoff, K; Wong, RK, 2010) |
| "Complications of esophageal cancer are particularly frequent in cases of hypopharyngeal cancer in comparison to other head and neck tumors." | ( Egawa, S; Furuya, A; Kobayashi, S; Mori, T; Ono, T; Sanbe, T; Shimane, T; Suzaki, H, 2010) |
| "Esophageal cancer is the second most common cancer among Indian males and is mostly associated with tobacco smoking and alcohol consumption." | ( Devaraj, H; Devaraj, SN; Dhayaparan, D; Jayanthi, V; Parthasarathy, S, 2011) |
| "Behaviors of esophageal cancer are different according to the geographic distribution." | ( Bagheri, R; Maddah, G; Roodbari, S; Sadeghian, MH; Saedi, HS, 2011) |
| "Oesophageal cancer is a highly aggressive tumour entity with at present poor prognosis." | ( Alves, F; Dai, G; Dullin, C; Fischer, JW; Freudenberger, T; Homey, B; Jannasch, K; Knoefel, WT; Poscher, E; Prenzel, K; Savani, RC; Stoecklein, NH; Twarock, S, 2011) |
| "Barrett's esophageal cancer is usually included in gastroesophageal (GE) junction adenocarcinoma in Japanese people." | ( Abe, Y; Horii, T; Iijima, K; Imatani, A; Kikuchi, R; Koike, T; Ohara, S; Shimosegawa, T; Unakami, H, 2011) |
| "Esophageal cancer is an extremely lethal human disease." | ( Carballo, M; Maish, MS; Yetasook, A, 2011) |
| "Because most esophageal cancers are diagnosed at an advanced stage, a majority of patients require palliative dysphagia treatment." | ( Butruk, E; Fijuth, J; Kraszewska, E; Polkowski, M; Regula, J; Rupinski, M; Wronska, E; Zagorowicz, E, 2011) |
| "Esophageal cancer is one of the most common malignancies and is associated with a dismal prognosis." | ( Cao, Q; Ji, X; Liu, X; Lu, A; Meng, F; Sang, M; Shan, B; Wang, L, 2011) |
| "Esophageal cancer is an aggressive cancer with poor prognosis." | ( Hirano, S; Kondo, S; Miyamoto, M; Shichinohe, T; Tsuchikawa, T; Yamamura, Y, 2012) |
| "Oesophageal cancer is the ninth most common cancer in the world and the second most common cancer among South African men." | ( Cronjé, MJ; Joubert, AM; Skerman, NB, 2011) |
| "Oesophageal cancer is the 7th most common cause of cancer-related death in the developed world and the incidence of oesophageal adenocarcinoma is now the fastest growing of any gastrointestinal cancer." | ( Ahmed, K; Hanna, GB; Kayani, B; Zacharakis, E, 2011) |
| "Oesophageal cancer is endemic in some regions of the Islamic Republic of Iran and efforts have made to find factors that play a role in its prognosis." | ( Alibakhshi, A; Aminian, A; Dashti, H; Ghaderi, H; Hasani, SM; Jahangiri, Y; Karimian, F; Meysamie, A; Mirsharifi, R, 2011) |
| "Esophageal cancer is the sixth most common cause of cancer-related death worldwide." | ( Cai, RG; Chen, L; Fan, QX; Hao, XZ; Huang, J; Liu, AN; Sun, Y; Wang, JW, 2011) |
| "Esophageal cancer is a highly aggressive disease, and improved modalities for its treatment are needed." | ( Doki, Y; Fujiwara, S; Gnjatic, S; Hatazawa, J; Kanto, T; Kawabata, R; Kawada, J; Kurokawa, Y; Miyata, H; Mori, M; Nakajima, K; Nakamura, Y; Nakayama, E; Nishikawa, H; Sakakibara, M; Sato, E; Sedrak, C; Shimosegawa, E; Takahashi, T; Takiguchi, S; Wada, H; Yamasaki, M, 2012) |
| "Esophageal cancer is recognized as one of the most refractory pernicious diseases." | ( Hu, X; Huang, W; Jing, X; Liu, L; Liu, S; Tong, T; Wang, R; Wu, W; Yue, J; Zheng, Y, 2012) |
| "Esophageal cancer is an intractable disease due to late diagnosis, high incidence of post-surgical locoregional recurrence and frequent distant metastasis." | ( Dong, Z; Jiang, Y; Li, P; Liu, K; Lu, J; Ma, J; Yang, H; Zhao, J; Zhao, M, 2012) |
| "Esophageal cancer is the seventh leading cause of cancer death in males in USA, and there is a strong link has been demonstrated between inflammation and esophageal cancer, interleukin (IL)-32 is a recently described pro-inflammatory cytokine characterized by the induction of nuclear factor NF-κB activation, the p38MAPK also plays an important role in key cellular processes related to inflammation and cancer." | ( Adrienne, J; Al-Amran, FG; Hadi, N; Lee, J; Yousif, NG, 2013) |
| "Esophageal cancer is a common malignancy with a high mortality rate." | ( Cai, Y; Hu, M; Jiang, F; Liu, C; Liu, Q; Luo, J; Luo, M; Shi, Q; Song, P; Tang, M; Weng, Y; Yang, D; Zhan, X; Zhang, F; Zhang, Y; Zhou, L; Zuo, G, 2013) |
| "Esophageal cancer is unusually frequent in Western Kenya, despite the low prevalence of classical risk factors such as heavy drinking and tobacco smoking." | ( Abnet, CC; Bowyer, P; Collins, R; Dawsey, SM; Dawsey, SP; Freedman, ND; Mwachiro, M; Nieminen, MT; Novak-Frazer, L; Rautemaa, R; Salaspuro, M; White, RE, 2013) |
| "Oesophageal cancer is a global heath problem." | ( Chen, X; Chen, XY; Huang, Y; Li, H; Shao, Y; Wen, Y; Wu, S; Xian, L; Yang, C; Yang, S; Zheng, J, 2012) |
| "Esophageal cancer is a common malignant tumor occurring in human esophageal epithelial tissue." | ( Huang, GL; Sun, GJ; Wang, SK; Wang, TT; Yang, L; Yang, LG, 2012) |
| "Esophageal cancer is a disease that is difficult to manage before and after surgery and is associated with a high in-hospital mortality rate despite there being reports of improved outcomes after multidisciplinary treatment." | ( Akami, T; Matsumura, A; Matsuyama, T; Mugitani, T; Nishibeppu, K; Ogino, S; Shimode, Y; Takemura, M, 2013) |
| "Esophageal cancer is characterized by increased oxidative stress and the production of 8-hydroxy-2'-deoxyguanosine (8-OHdG), which is one of the main mutagenic modifications of DNA." | ( He, H; Wang, C; Wang, N; Zhang, L; Zhao, Y, 2014) |
| "Esophageal cancer is the sixth most common cause of cancer-related deaths worldwide." | ( Cheung, AL; Guan, XY; Law, S; Li, B; Li, J; Qin, YR; Tsao, SW; Xu, WW; Zhang, LY, 2014) |
| "Esophageal cancer is one of the most common cancers in North East India." | ( Das, M; Mahanta, J; Phukan, RK; Saikia, BJ; Sekhon, GS; Sharma, SK, 2015) |
| "Esophageal cancer is the eighth most common cancer in the world and ranks as the sixth leading cause of cancer-related mortality." | ( Chen, Z; Gao, Y; He, J; Li, J; Luo, M; Pu, J; Shi, X; Sun, H; Yao, R; Zhou, C; Zhou, F, 2015) |
| "Esophagectomy for esophageal cancer is one of the most invasive operative procedures." | ( Kawakubo, H; Kitagawa, Y; Matsuda, S; Miyasho, T; Nakamura, R; Ogura, M; Okamura, A; Saikawa, Y; Takahashi, T; Takeuchi, H; Wada, N, 2015) |
| "Esophageal cancer is thought to be the most malignant neoplasm due to its biological aggressiveness." | ( Akutsu, Y; Matsubara, H, 2015) |
| "Esophageal cancer is a common malignant tumor worldwide with a high incidence rate in China and it is a great threat to human health." | ( Liu, L; Wang, J; Zuo, J; Zuo, LF, 2015) |
| "Currently, esophageal cancer is rarely curable, and herein, a paclitaxel or 5-fluorouracil/esophageal stent combination (PTX or 5-FU/stent) was used to provide a new approach to treat this cancer." | ( Chen, W; Guo, S; Li, J; Liu, J; Shen, Y; Wang, Z; Wu, K, 2015) |
| "Esophageal cancer is most frequently treated with platinum-based chemoradiotherapy (CRT)." | ( Emi, M; Hamai, Y; Hihara, J; Kenjo, M; Murakami, Y; Nagata, Y; Okada, M, 2015) |
| "Esophageal cancers are highly aggressive tumors with poor prognosis despite some recent advances in surgical and radiochemotherapy treatment options." | ( Ahrens, TD; Boerries, M; Busch, H; Follo, M; Hembach, S; Hoeppner, J; Hopt, UT; Lassmann, S; Ostendorp, J; Timme, S; Werner, M, 2015) |
| "Esophageal cancer is one of the most frequent causes of cancer-related deaths worldwide." | ( Ishimine, H; Ito, Y; Kurisaki, A; Seki, Y; Sumitomo, K; Yoshida, Y; Zhou, R, 2016) |
| "Esophageal cancer is of high prevalence and poor prognosis." | ( Dong, W; Li, J; Liao, F; Wang, J; Wu, D; Zhang, J, 2016) |
| "Esophageal cancer is a major global health burden with a strong host-environment interaction component and epigenomics underpinnings that remain to be elucidated further." | ( Borthakar, BB; Chattopadhyay, I; Kapur, S; Kataki, AC; Mahanta, J; Phukan, RK; Rai, AK; Saxena, S; Sharma, J; Singh, LC; Singh, V; Vasudevan, M, 2015) |
| "Esophageal cancer is ranked as the eighth most common cancer and the sixth leading cause of cancer deaths worldwide." | ( Cal, S; Dai, W; Ip, JC; Ko, JM; Lung, ML; Ng, HY; Yu, VZ, 2016) |
| "Oesophageal cancer is a highly aggressive disease with about 50% of patients presenting with advanced or metastatic disease at initial diagnosis." | ( Bai, L; Cheng, Z; Dai, G; Han, Z; Liang, P; Liu, F; Tan, S; Yu, J; Yu, X; Zhou, F, 2016) |
| "Esophageal cancer is one of the most common cancers worldwide, and the incidence and mortality is increasing rapidly in recent years in China, but the underlying mechanisms are largely unclear." | ( Bao, Y; Chen, Z; Dong, H; Guo, Y; Li, K; Shen, K; Wang, Q; Yang, W; Yang, Y; Zhang, H, 2016) |
| "Esophageal cancer is one of the least studied and deadliest cancers worldwide with a poor prognosis due to limited options for treatment." | ( Bode, AM; Chen, H; Dong, Z; Jiang, Y; Li, H; Li, W; Liu, K; Ma, WY; Oi, N; Reddy, K; Saleem, M; Sheng, Y; Wu, Q; Yao, K; Zhang, Y, 2016) |
| "Esophageal cancer is one of the leading cause of cancer mortality in the world." | ( Fan, L; He, Z; Hu, X; Jin, Z; Kang, Q; Kong, X; Li, Y; Liao, C; Liu, L; Wang, Y; Wu, H; Wu, X; Xiao, X; Xu, H; Zeng, Y; Zhang, J; Zheng, K, 2016) |
| "Esophageal cancer is the fourth most common gastrointestinal cancer, it generally has a poor prognosis and novel strategies are required for prevention and treatment." | ( Hou, L; Wu, K; Yang, L; Yang, P; Zhang, L; Zhao, J, 2016) |
| "Esophageal cancer is a deadly disease in the esophagus with a poor prognosis." | ( Fu, S; He, Q; Zhang, Z; Zheng, Z, 2017) |
| "Esophageal cancer is one of the most aggressive tumor types because of its invasiveness and metastatic potential." | ( Fushida, S; Harada, S; Hayashi, H; Kinoshita, J; Makino, I; Miyashita, T; Nakanuma, S; Nakayama, A; Ninomiya, I; Ohta, T; Okamoto, K; Oyama, K; Sakai, S; Tajima, H; Takamura, H; Tsukada, T, 2016) |
| "Esophageal cancer is one of the top leading causes of cancer-related deaths in Malaysia." | ( Norsa'adah, B; Siti-Azrin, AH; Wan-Nor-Asyikeen, WA, 2016) |
| "Esophageal cancer is one of the common malignancies worldwide, particularly in eastern African and Asian countries including Japan." | ( Chen, N; Horii, A; Saiki, Y; Sumarpo, A; Sunamura, M; Wang, R, 2016) |
| "Esophageal cancer is an aggressive tumor and is the sixth leading cause of cancer death worldwide." | ( Brandão, CA; Cappellari, AR; Coutinho-Silva, R; da Silva, VD; de Marchi, FO; Gehring, MP; Lopes, TG; Moreira-Souza, ACA; Morrone, FB; Paccez, JD; Pinto, LFR; Santos, AA; Savio, LEB; Zaparte, A; Zerbini, LF, 2017) |
| "Esophageal cancer is the eighth most common cancer worldwide." | ( Chen, Y; Hao, D; He, C; Liu, J; Wang, J; Wang, W; Wu, X; Xing, W; Yang, Y, 2017) |
| "Esophageal cancer is one of the most common type of malignancies." | ( Dong, Y; He, Q; Liu, Y; Wang, H; Zhou, J, 2017) |
| "Oesophageal cancer is one of the most common malignancies worldwide,and oesophageal squamous cell carcinoma (ESCC) is the predominant histological type both globally and in China." | ( Feng, X; Gao, Y; He, J; Li, Z; Shao, F; Shi, S; Wang, C; Yang, X, 2017) |
| "Esophageal cancer is a common gastrointestinal cancer, with a very high mortality rate in patients with metastasis." | ( Hu, Y; Li, J; Li, X; Ma, J; Sun, D; Tao, H; Wang, L; Zhang, G, 2018) |
| "As oesophageal cancer is one of the most aggressive gastrointestinal cancers, we aimed to clarify the effect of Nrf2 on metabolic reprogramming in oesophageal cancer." | ( Baba, H; Baba, Y; Ishimoto, T; Iwatsuki, M; Kitano, Y; Miyake, K; Nakagawa, S; Nakao, M; Watanabe, M; Yamashita, YI; Yoshida, N, 2018) |
| "Esophageal cancer is a common malignant tumor worldwide." | ( Du, X; Li, M; Liu, K; Sun, Q; Wang, L; Wang, Y; Wu, J; Zang, W; Zhao, G, 2018) |
| "Esophageal cancer is the 8th most common cancers worldwide and the 6th most common cause of death among cancers." | ( Chen, G; Kang, X; Liu, TD; Zhang, JX; Zheng, BZ, 2018) |
| "Esophageal cancer is associated with a high mortality rate and easy metastasis." | ( Chen, YJ; Huang, PI; Liu, YK; Liu, YM; Tsai, TH, 2018) |
| "Esophageal cancer is one of the worst malignant digestive neoplasms with poor treatment outcomes." | ( Liu, F; Song, Y; Wang, W; Xing, D, 2018) |
| "Esophageal cancer is one of the most common cancers in the world." | ( Chen, T; Dong, X; Li, Y; Ma, H; Meng, X; Qi, D; Su, J; Wang, W; Yang, L; Zhang, X, 2018) |
| "Esophageal cancer is one of the common causes of cancer mortality in the world." | ( Feng, Y; Jia, X; Li, N; Lu, F; Xu, M; Yang, CS; Yang, H; Zhang, Q, 2018) |
| "Esophageal cancer is the eighth most prevalent cancer and has high mortality in our society." | ( Fang, M; Hua, P; Liu, T; Lu, Z; Wu, M; Zhang, G; Zhang, Y, 2018) |
| "Esophageal cancer is a common gastrointestinal cancer." | ( Feng, X; Liu, Q; Qu, F; Shi, Y; Wang, P; Wang, S; Wang, X; Wu, L; Zhang, B; Zhang, K, 2018) |
| "Esophageal cancer is a common malignant tumor with an increasing trend during the past three decades." | ( Azizian, M; Derakhshani, M; Ghasemi, F; Hedayt, P; Hesari, A; Mahinparvar, N; Mirzaei, H; Nesaei, A; Sanaei, S; Sheikhi, A, 2019) |
| "Esophageal cancer is one of the leading causes of cancer death in the male population of Eastern Asia." | ( Chen, LH; Chuang, EY; Hsieh, YC; Lai, LC; Lee, JM; Lin, WC; Tsai, MH; Yang, PW, 2019) |
| "Esophageal cancer is a very deadly disease, killing more than 15,000 people in the United States annually." | ( Kang, Y, 2019) |
| "Esophageal cancer is one of the most common malignant tumors, characterized by early metastasis and high degree of malignancy." | ( Chai, T; Chen, S; Kang, M; Lin, J; Lin, W; Lin, Y; Shen, Z; Zhang, P; Zhang, Z, 2019) |
| "Esophageal cancer is one of the most common cancers around the world, and it has high incidence and mortality rates." | ( Jiao, GH; Qiu, ZH; Zhang, HH; Zhang, WW, 2019) |
| "Esophageal cancer is prevalent in Cixian, China, but the etiology of this disease remains largely unknown." | ( Elzawahry, A; He, Y; Hosoda, F; Inoue, M; Ishino, K; Kato, M; Kikuchi, S; Li, D; Lin, Y; Liu, J; Matsuda, T; Matsushima, Y; Meng, F; Nagai, M; Nakagama, H; Nakamura, H; Qiao, Y; Sato, H; Shan, B; Shibata, T; Song, G; Totoki, Y; Totsuka, Y; Wei, W, 2019) |
| "Esophageal cancer is a common human malignant tumor with high mortality." | ( He, S; Li, L; Liu, J; Peng, J; Wang, W; Wu, X; Xu, Y; Yu, J; Zhang, J; Zhang, R, 2019) |
| "Background Esophageal cancer is a very common malignant tumor in China, especially esophageal squamous cell carcinoma (ESCC), but there is currently no effective treatment for patients after first-line chemotherapy failure." | ( Lei, J; Song, X; Wang, Y; Yu, J; Zhang, C; Zhang, N; Zhang, S; Zhao, J, 2020) |
| "Esophageal cancer is a prevalent type of cancer worldwide and is ranked sixth among cancer-associated mortalities." | ( Anasihan, G; Chen, L; Dai, Y; Ha, YNE; Pidayi, M; Wufuer, D, 2020) |
| "Esophageal cancer is a highly fatal malignant neoplasm, with 2 etiologically different histological types." | ( Lagergren, J; Ness-Jensen, E; Santoni, G; Wang, QL; Xie, SH, 2020) |
| "Esophageal cancer is a digestive tract malignancy, ranking sixth among the world's deadliest tumor incidence." | ( Li, S; Liang, Y; Zhang, L; Zheng, G, 2020) |
| "Esophageal cancer is an aggressive malignancy, and its current treatment strategies are plagued with high rates of recurrence." | ( Liu, H; Wei, W; Yao, Y; Yuan, J, 2021) |
| "Esophageal cancer is increasingly common and carries a poor prognosis." | ( Bateman, A; Byrne, JP; Grace, BL; Iveson, T; Jackson, A; Kelly, JJ; Noble, F; Pucher, PH; Rahman, SA; Rees, C; Underwood, TJ; Walker, RC, 2020) |
| "Oesophageal cancer is the 6th most common cause of cancer related death worldwide." | ( Buckley, AM; Clarke, N; Davern, M; Dunne, MR; Foley, EK; Kennedy, BN; Kennedy, SA; Lysaght, J; MacCarthy, F; Morrissey, ME; Nolan, A; O'Sullivan, J; O'Toole, D; Ravi, N; Reynolds, JV, 2020) |
| "Esophageal cancer is one of the fatal cancers around the world." | ( Bai, Y; He, H; Huang, L; Liu, W; Zhang, P, 2020) |
| "Esophageal cancer is one of the most common cancer with limited therapeutic strategies, thus it is important to develop more effective strategies to against it." | ( Han, S; Ma, J; Wang, HD; Wang, Y; Wang, Z; Yuan, Q, 2020) |
| "Oesophageal cancer is one of the most frequent solid malignancies and the leading cause of cancer-related death around the world." | ( Jiang, HM; Lan, J; Liu, SN; Lv, J; Qi, D; Wu, MD; Xu, JL; Yang, Y; Yuan, YJ; Zhai, J, 2020) |
| "Esophageal cancer is one of the most frequently occurring malignancies in China, and the incidence of esophageal cancer ranks 8th in the world." | ( Chen, Y; Wang, Z; Xiang, M, 2021) |
| "BACKGROUND Esophageal cancer is a common gastrointestinal malignancy in China." | ( Hu, L; Jiang, X; Kong, Z; Meng, Q; Wang, J; Yu, J; Zhou, M, 2020) |
| "Esophageal cancer is a disease showing poor prognosis." | ( Fujiwara, T; Kato, T; Katsura, Y; Kikuchi, S; Matsukawa, A; Narusaka, T; Nishiwaki, N; Noma, K; Ohara, T; Sato, H; Shirakawa, Y; Tazawa, H; Tomono, Y, 2021) |
| "Oesophageal cancer is categorised among the most fatal cancers across the world with a mortality ranking of sixth position." | ( Govero, AB; Kukhon, FR; Sanghavi, DK; Yarrarapu, SNS, 2021) |
| "Esophageal cancer is a malignancy that has a poor prognosis, which is mainly due to patients presenting once the cancer is in the advances stages." | ( Fatehi Hassanabad, A; Wong, JVS, 2021) |
| "Esophageal cancer is a malignant tumor of the digestive tract that is difficult to diagnose early." | ( Li, FR; Xue, XJ; Yu, J, 2021) |
| "Oesophageal cancer is the seventh most common cancer in the world and adenocarcinoma is the dominant subtype in Western industrialised nations." | ( Due, SL; Hussey, DJ; Watson, DI, 2021) |
| "Esophageal cancer is one of the most common malignant tumors of the digestive system, with high incidence and mortality." | ( Gao, YM; Li, C; Li, MY; Liu, WY; Ma, YQ; Shi, Y; Song, JW; Wang, B; Wang, H, 2022) |
| "Esophageal cancer is the most common gastrointestinal tumor and is difficult to be eradicated with conventional treatment." | ( Chen, T; Chen, ZL; Li, MY; Meerovich, G; Mi, L; Soe, TW; Than, NN; Yan, YJ, 2022) |
| "Esophageal cancer is the seventh most common cancer globally." | ( Deng, DX; Heng, JH; Huang, HC; Li, EM; Li, RY; Li, ZM; Liao, LD; Lin, W; Xu, HY; Xu, LY; Xu, XE; Zheng, YQ; Zheng, ZY, 2022) |
| "Esophageal cancer is a relatively rare cancer." | ( Che, W; Chen, Y; Liang, H; Peng, F; Wu, B; Xie, X, 2022) |
| "Esophageal cancer is a very deadly disease ranking 8th most common cancer in terms of incidence and the 6th highest in terms of mortality both in the USA and around the world." | ( Farooq, T; Farooq, Z; Irfan, A; Muddassir, K; Qayyum, MA; Sultan, MH, 2022) |
| "Esophageal cancer is the sixth leading cause of cancer death worldwide with considerable geographical histological variation There is a paucity of data in esophageal cancer in demographics, histology, and survival among the multi-ethnic Malaysian population." | ( Lim, RZM; Mahendran, HA, 2022) |
| "Esophageal cancer is a leading cause of cancer deaths worldwide, with an increasing incidence in recent decades." | ( Gibson, MK; Weidenbaum, C, 2022) |
| "Esophageal cancer is one of the most common malignancies which induces cancer-related death." | ( Gong, L; Hu, Y; Li, Z; Song, Z, 2022) |
| "Esophageal cancer is the most prevalent digestive system tumor." | ( Cheng, C; Li, T; Liu, Y; Lu, H; Mao, Q; Peng, C; Shen, B; Shi, M; Xiao, T; Yang, A, 2022) |
| "Esophageal cancer is one of the leading causes of cancer death and the seventh most prevalent cancer worldwide." | ( Jafari, SM; Joshaghani, H; Sheikh Arabi, M; Younesian, O, 2023) |
| "Esophageal cancer is a lethal disease that frequently occurs in developing countries, the incidence of which could be declined by drinking EGCG-enriched drinks or food." | ( Chen, Z; Lin, X; Teng, Q; Wei, Y; Wu, F; Zheng, Y; Zhou, F; Zhu, H, 2022) |
| "Esophageal cancer is a lethal disease that frequently occurs in developing countries, the incidence of which could be declined by drinking EGCG-enriched drinks or food." | ( Chen, Z; Lin, X; Teng, Q; Wei, Y; Wu, F; Zheng, Y; Zhou, F; Zhu, H, 2022) |
| "Esophageal cancer is a highly aggressive malignancy with a low response to standard anti-cancer therapies." | ( Jing, X; Wang, T; Zhang, F; Zhao, W, 2023) |
| "Esophageal cancer is a common digestive tract malignant tumor." | ( Li, S; Liang, Y, 2023) |
| "Esophageal cancer is one of the major life-threatening diseases in the world." | ( Han, Y; Li, B; Li, H; Meng, W, 2023) |
| "Esophageal cancer is the seventh most common cancer in the world." | ( Deng, DX; Heng, JH; Li, EM; Liao, LD; Lin, W; Liu, LX; Xu, LY; Xu, XE; Zhao, H; Zheng, ZY, 2023) |
| "Surgery for esophageal cancer is associated with high mortality and morbidity, especially in low and middle-income countries." | ( Arora, A; Khurana, G; Ramakrishnan, P; Saini, S, 2023) |
| "Esophageal cancer is a highly malignant disease with poor prognosis." | ( Gao, Y; Sheng, G; Wang, T; Wu, H; Wu, J, 2023) |
| "Esophageal cancer is the seventh most common malignancy worldwide and the sixth leading cause of cancer mortality with an overall survival rate of <20%." | ( Hsieh, YC; Wu, JS, 2023) |
| Excerpt | Reference |
|---|
| "Treatment of the human esophageal cancer cell line EC8712 with retinoic acid (RA) stopped the cell growth significantly and gave rise to terminal differentiation of the cells characterized by increased expression of involucrin gene." | ( Cai, Y; Feng, L; Fu, M; Tian, Y; Wang, XQ; Wang, ZH; Wu, M, 1992) |
| "The records of patients with esophageal cancer who were treated with a combined modality therapy were reviewed to determine the effects of simultaneously administered chemotherapy and radiotherapy (RT) at sites of recurrence and the relationship between treatment outcome and clinicopathologic variables." | ( Denham, JW; Devitt, PG; Gill, PG; Jamieson, GG; Olweny, C; Yeoh, E, 1992) |
| "Three cloned esophageal cancer cell lines, Cu3, Cu4 and Cu6, were established from Eca109 cancer cells, and four cloned esophageal cancer cell lines, Ct1, Ct2, Ct5 and Ct7, were established from Eca109 cancer cells after hematoporphyrin photodynamic therapy." | ( Ning, A, 1991) |
| "On the other hand, a clinical case of esophageal cancer with an estrogen receptor showed a growth inhibition of primary carcinoma cells by estradiol treatment." | ( Kido, Y; Matsuoka, H; Mitsudomi, T; Shirabe, K; Sugimachi, K; Ueo, H; Yano, K, 1990) |
| "The advantages of chemoradiotherapy in esophageal cancer could be summarized as follows: higher response rate (60-80%), higher proportion of complete responses (up to 45%), longer remission duration, lower radiation dosage (3,200-4,000 cGy) and consequently better tolerance of treatment (less morbidity)." | ( Kolarić, K, 1985) |
| "A series of 25 patients with advanced esophageal cancer treated from Mar." | ( Wang, ZY, 1986) |
| "Thirty patients with cancer of the esophagus were treated with multimodality therapy." | ( Chalaoui, J; Duprat, G; Duranceau, A; Robidoux, A; Sylvestre, J, 1987) |
| "Thirty-two cases of esophageal cancer were treated with thermochemotherapy from August 1984 to June 1985." | ( Hou, BS; Li, DJ, 1987) |
| "Thirty-four cases of esophageal cancer were treated by radiation combined with chemotherapy and hyperthermia (triple therapy) from September 1985 to January 1986." | ( Hou, BS; Li, DJ; Xiong, QB, 1989) |
| "Thirty-five consecutive esophageal cancer patients were treated by a combination regimen COPU (CTX 600-800 mg/m2, IV, on days 1, 8, 15 at 8 PM; VCR 1." | ( Qi, WB, 1989) |
| "Eleven patients with advanced oesophageal cancer were treated with carboplatin." | ( Mannell, A; Winters, Z, 1989) |
| "Three patients with esophageal cancer, who were treated by FT+BrdU+radiation with good results, are reported." | ( Hanyu, F; Ide, H; Kobayashi, S; Muto, H; Nakagawa, M; Shimamura, Y; Takasaki, K; Tanaka, S; Yamada, A; Yamamoto, M, 1987) |
| "Altogether 46 patients with esophageal cancer and stomach cancer with esophageal involvement were investigated before therapy." | ( Okulov, LV; Piperkova, EN; Shishkina, VV, 1988) |
| "The results of gamma-beam therapy of esophageal cancer leave much to be desired." | ( Azhigaliev, NA; Kusherbaev, SK; Sadykov, SS, 1988) |
| "The induction of esophageal cancer was enhanced by TPA given in drinking water after AMN administration; i." | ( Kuwano, H; Matsufuji, H; Mori, M; Sugimachi, K; Ueo, H, 1987) |
| "Fifty-seven patients with esophageal cancer were treated with curative intent between January 1979 and June 1985." | ( Bae, Y; Burdakin, J; Jacobsen, G; Lewis, J; Richmond, J; Seydel, HG, 1987) |
| "Twenty-four patients with squamous cell cancer of the esophagus were entered into a treatment protocol consisting of preoperative chemotherapy (CT), surgical resection (SR), and possible postoperative CT or radiation therapy (RT) beginning August 1981." | ( Carey, RW; Choi, NC; Grillo, H; Hilgenberg, AD; Mathisen, DJ; Wilkins, EW, 1986) |
| "For surgical treatment of esophageal cancer, the importance of evaluating lymph node metastasis and the lymph flow of the esophagus can not be overemphasized." | ( Aikou, T; Baba, M; Kajisa, T; Kuroshima, K; Natugoe, S; Tanabe, G; Yoshinaka, H, 1986) |
| "The incidence of esophageal cancer in oral administration group was 42." | ( Kobayashi, K, 1985) |
| "Ten patients with squamous cancer of the esophagus were treated with an outpatient regimen combining cis-diamminedichloroplatinum (II), methotrexate and bleomycin." | ( Greenwald, E; Kaplan, BH; Vogl, SE, 1981) |
| "Eight patients with esophageal cancer were treated by a new treatment schedule consisting of low dose irradiation, crescendo cisplatin and bleomycin polyacrylate pasta." | ( Lim, I; Mishina, H; Ogasawara, T; Okuyama, S; Taima, T; Yamagata, R; Yamamoto, K, 1983) |
| "Indications of surgical therapy for esophageal cancer patients with metastasis are limited." | ( Kasai, M; Nishihira, T, 1983) |
| "Twenty-one patients with squamous cell cancer of the esophagus were entered into a pilot clinical trial using preoperative chemotherapy (5-fluorouracil and cis-platinum) and radiation with the intent of improving cure rate and survival." | ( Dindogru, A; Kinzie, J; Leichman, L; MacKenzie, G; Seydel, HG; Shell, J; Steiger, Z; Toben, S, 1984) |
| "In the patients with esophageal cancer after MZ administration via the gastrostoma, the nature and time course of drug accumulation in the blood was identical, however accumulation maximum was lower and reached 219 +/- 25 micrograms/ml." | ( Dar'ialova, SL; Kiseleva, ES; Poliakov, PIu; Zel'vin, BM; Zimina, ES, 1984) |
| "Twelve patients with untreated cancer of the esophagus and 14 control subjects matched for age, smoking, and alcohol consumption were tested for taste thresholds." | ( Booth, P; Kamath, S; Kohrs, MB; Lad, TE; McGuire, WP, 1983) |
| "We report a case of double cancer of esophagus and stomach treated with 5-fluorouracil and consecutive low-dose cisplatin." | ( Akiyama, S; Hibi, K; Ito, K; Kasai, Y; Kondo, K; Nonami, T; Takagi, H, 1995) |
| "Conventional treatment of esophageal cancer with surgery or radiation alone has afforded few long-term survivors." | ( Chang, HS; Choi, EK; Kim, SB; Kim, SH; Kim, SW; Lee, JS; Lee, JW; Lee, KH; Song, HY; Suh, CW, 1995) |
| "Sixteen inoperable esophageal cancer patients, including six over 80 years of age, were given combined chemoradiation therapy." | ( Ashizawa, A; Katsuta, T; Kinoshita, T; Kobayashi, M; Miyahara, M; Saito, T; Shigemitsu, Y; Shimoda, K, 1993) |
| "Thirty-five patients with oesophageal cancer were treated with external beam irradiation (50-60 Gy) followed by a boost-dose of 15-20 Gy by means of low dose rate intraluminal brachytherapy." | ( Caspers, RJ; Davelaar, J; Griffioen, G; Leer, JW; Sewsingh, EN; Welvaart, K; Zwinderman, AH, 1993) |
| "Ten patients with inoperable advanced esophageal cancer were treated with endoscopic local injection of PEP-CH combined with radiation using 60Co." | ( Hagiwara, A; Kojima, O; Oyama, T; Ozaki, K; Sakakibara, T; Sakakura, C; Sasaki, S; Shimotsuma, M; Takahashi, T; Tsujimoto, H, 1993) |
| "Neoadjuvant therapy for cancer of the esophagus and cardia results in good tumor response." | ( Drinkard, LC; Ferguson, MK; Haraf, DJ; Hoffman, PC; Reeder, LB; Vokes, EE, 1995) |
| "Preoperative chemotherapy for esophageal cancer was performed and the toxic effects, post-operative complications, histological effects and survival time were evaluated." | ( Abe, T; Fujita, M; Hosokawa, M; Ishihara, K; Kusano, M; Miura, T; Ohara, M; Okayasu, T; Tanabe, Y; Yamazaki, S, 1995) |
| "Treatment of esophageal cancer has been primarily palliative." | ( Bates, DM; Clyde, JC; Garcia, JM; Girvin, GW; Lin, PH; Matsumoto, GH, 1995) |
| "In one case with esophageal cancer, clinical symptoms persisted after the start of antimicrobial chemotherapy and the patient died 10 days later associated with complications of esophageal cancer." | ( Kikuchi, K; Kobayashi, M; Okada, S; Oomori, Y; Shimizu, K; Tomonaga, O; Totsuka, K; Yoshida, K, 1994) |
| "An advanced esophageal cancer patient with multiple liver metastases was treated with a combination of CDDP, 5-FU and THP-ADM." | ( Anai, H; Ichiyoshi, Y; Matsuzaki, K; Minamisono, Y; Miura, O; Nagasaki, S; Toda, T, 1993) |
| "Surgical treatment of cancer of the esophagus is influenced by two issues: use of surgical resection within a multimodality treatment approach and selection of the correct surgical approach." | ( DeCamp, MM; Sugarbaker, DJ, 1993) |
| "Current and proposed trials in esophageal cancer have changed their focus accordingly to meet this new treatment challenge." | ( Coia, LR, 1993) |
| "Four patients with esophageal cancer and one patient with gastric cancer were treated with high-dose drip infusions of DDP to a total daily dose of 70-80 mg/m2." | ( Ando, N; Hoshiya, Y; Kitajima, M; Kubota, T; Kumai, K; Kurihara, N; Otani, Y, 1996) |
| "We conclude that inoperable esophageal cancer can be treated successfully by radiotherapy with a curative intent." | ( Calais, G; Chauvet, B; Geara, F; Le Floch, O; Reynaud-Bougnoux, A, 1990) |
| "From January 1990 to April 1993, 60 oesophageal cancer patients were enrolled in a protocol of non-surgical treatment that consisted of induction chemotherapy followed by concurrent chemoradiotherapy." | ( Aman, E; Barugel, M; Blajman, C; Carraro, S; Fiorini, A; Giglio, R; Gonzalez, G; Jarentchuk, A; Kneitschel, R; Milano, C; Nadal, J; Navigante, A; Pennella, E; Roca, E; Santarelli, MT; Sardi, M, 1996) |
| "Since 1984, 373 patients with oesophageal cancer have been treated on three prospective, but unrandomised, protocols involving radiation with concurrent cisplatin and infusional fluorouracil." | ( Burmeister, BH; Denham, JW; Hamilton, CS; Joseph, DJ; Lamb, DS; O'Brien, P; Spry, NA; Walker, QJ; Yeoh, E, 1996) |
| "In patients with esophageal cancer, combined chemotherapy is usually given as a part of multimodality treatment and therefore undesirable toxicity should be diminished." | ( Eguchi, R; Hayashi, K; Ide, H; Nakamura, T, 1996) |
| "Twenty-five patients with esophageal cancer were treated in a phase I pilot protocol consisting of initial esophagectomy with gastroesophagostomy and subsequent combined chemotherapy and radiation." | ( Doolas, A; Ebie, N; Griem, K; Hartsell, W; Kang, HJ; Millikan, K; Murthy, AK; Recine, DC; Taylor, S, 1997) |
| "One case of esophageal cancer, 7 of gastric cancer, 2 of colorectal cancer, 1 of carcinomatous peritonitis from unknown origin, and 1 of hepatocellular carcinoma, were treated by daily low-dose cisplatin combined with 5-FU or tegafur, and their ECOG Performance Status Score (PS), number of lymphocytes, and CD3 zeta chain expression of peripheral blood lymphocytes were studied to compare with the effects of treatment." | ( Hada, M; Horigome, M; Iida, B; Koshizuka, K; Mutoh, S; Nakagomi, H; Tada, Y; Takano, K; Watanabe, K; Yamadera, Y, 1997) |
| "In patients with squamous-cell esophageal cancer, preoperative chemoradiotherapy did not improve overall survival, but it did prolong disease-free survival and survival free of local disease." | ( Bosset, JF; Elias, D; Gignoux, M; Lozach, P; Mantion, G; Mercier, M; Ollier, JC; Pavy, JJ; Sahmoud, T; Tiret, E; Triboulet, JP, 1997) |
| "Trimodality treatment for esophageal cancer may provide long-term survival in some patients regardless of their pCR status." | ( Bernard, SA; Detterbeck, FC; Egan, TM; Jones, DR; Parker, LA; Tepper, JE, 1997) |
| "In the management of esophageal cancer, endoscopy has evolved from a tool used to provide biopsy confirmation of suspected tumor to an integral part of the staging and ongoing treatment of patients." | ( Kimmey, MB; Ponec, RJ, 1997) |
| "Salvage surgery for the T4 esophageal cancer following downstaging by neoadjuvant chemo-radiotherapy has become to be available." | ( Ando, N; Kitagawa, Y; Kitajima, M; Ozawa, S; Takeuchi, H, 1997) |
| "Forty patients with esophageal cancer were treated in a phase I and II trial of induction chemotherapy (cisplatin, 5-fluorouracil, and paclitaxel) at three dosage levels (75, 125, and 100 mg/m2) and concurrent hyperfractionated radiotherapy (45 Gy to the mediastinum, 58." | ( Carey, RW; Choi, NC; Grillo, HC; Grossbard, ML; Lynch, TJ; Mathisen, DJ; Moncure, AC; Wain, JC; Wright, CD, 1997) |
| "The treatment of patients with thoracic esophageal cancer invading adjacent organs is controversial." | ( Kobori, O; Muto, T; Nagawa, H; Seto, Y, 1997) |
| "Patients with localized esophageal cancer also received radiation therapy beginning on day 1 (1." | ( Greco, FA; Hainsworth, JD; Meluch, AA, 1997) |
| "Two of five patients with esophageal cancer responded (partial response) to this treatment." | ( Gadgeel, S; Hussain, M; Philip, PA; Shields, A; Zalupski, MM, 1997) |
| "Pretreatment of esophageal cancer cells with 9-cis-retinoic acid did not substantially potentiate flavopiridol activity in these cell lines." | ( Altorki, NK; Chen, GA; Matthews, W; Mixon, A; Schrump, DS, 1998) |
| "A series of patients with esophageal cancer was treated with chemotherapeutic regimens of the new antitumor platinum preparation nedaplatin plus 5-FU in combination with radiation therapy, and the therapeutic responses, side effects, and complications were clinically assessed." | ( Asai, A; Hioki, K; Michiura, T; Mori, T; Motohiro, T; Yamanaka, H, 1998) |
| "Advanced gastric, colon and esophageal cancers (n = 21) were treated with 5-FU (250 mg) modulated by CDDP (5 mg)." | ( Hisano, H; Kida, H; Nomura, M; Shibasaki, S; Shinkai, K; Yano, H, 1999) |
| "We describe a case of advanced esophageal cancer treated successfully by chemotherapy with nedaplatin alone." | ( Fukuda, S; Hizawa, Y; Munakata, A; Saitoh, S; Sakata, Y; Satoh, T; Takasugi, T; Tamura, Y; Tohno, H; Tsushima, K; Yamada, Y, 1999) |
| "The cases with esophageal cancer, stomach cancer, pancreatic cancer, hepatocellular carcinoma or colonic cancer co-existing with their inoperable lesion(s) were considered in this chemotherapy." | ( Denno, R; Hirata, K; Kimura, H; Mukaiya, M; Oikawa, I; Sasaki, K; Shirasaka, T; Tsuji, A; Yamamitsu, S, 1999) |
| "Sixty-four patients with advanced oesophageal cancer were treated with a cisplatin dose of 60 mg m(-2) and increasing doses of paclitaxel from 100 mg m(-2) up to 200 mg m(-2) both administered over 3 h for a maximum of six cycles in patients with stable disease or eight cycles in responding patients." | ( Kerkhofs, L; Kok, TC; Siersema, PD; Splinter, TA; Tilanus, HW; van der Gaast, A, 1999) |
| "The treatment of upper thoracic esophageal cancer remains challenging, and combined treatment is necessary to improve the outcome." | ( Doki, Y; Inoue, M; Monden, M; Shiozaki, H; Tsujinaka, T; Yamamoto, M; Yano, M, 1999) |
| "Three cases of prominent-type advanced esophageal cancer were treated with chemoradiation therapy using a 5-FU analog and low dose CDDP." | ( Fukao, K; Kawai, Y; Kawamoto, T; Koike, N; Maruyama, T; Monoi, H; Ohara, K; Shimizu, W; Todoroki, T; Yamamoto, Y; Yoshida, S, 1999) |
| "A 63-year-old male with an esophageal cancer invading the bronchus was treated with radiation therapy (70 Gy) from November 1995, resulting in the disappearance of the lesion." | ( Hada, T; Kobayashi, I; Kohno, S; Matai, K; Oda, Y; Ohmori, H; Sasaya, K; Yamazaki, Y, 1999) |
| "It seems likely that survival in oesophageal cancer is improved by multimodal therapy encompassing radiotherapy, chemotherapy and surgery." | ( Frey, E; Schefer, H; Thum, P, 1999) |
| "Fifty-three patients with localized esophageal cancer received concurrent chemoradiotherapy followed by brachytherapy." | ( Dokiya, T; Oki, Y; Yorozu, A, 1999) |
| "Local control of esophageal cancer is excellent following neoadjuvant chemotherapy and radiation therapy." | ( Adelstein, DJ; Becker, M; Chidel, MA; Kupelian, PA; Rice, TW; Suh, JH, 1999) |
| "Multimodality therapy of esophageal cancer has been evaluated in several clinical trials, with positive results in terms of improved survival compared with single-modality therapy." | ( Wright, CD, 1999) |
| "A 64-year-old man with unresectable esophageal cancer (A3, N1, M0) was treated with concurrent chemoradiotherapy." | ( Inoue, H; Ise, H; Matsumoto, G; Matsuo, S; Suzuki, N, 1999) |
| "The early detection of superficial esophageal cancer and dysplasia in asymptomatic patients with HNC, after successfully treating the primary cancer, may provide an effective cure." | ( Altemani, A; Brandalise, N; Lage, HT; Martins, AS; Molina, G; Scanavini, RC; Tincani, AJ; Valério, JB, 2000) |
| "It is possible to cure oesophageal cancer with chemo-radiotherapy and selective oesophagectomy, and achieve organ preservation in the majority of long term survivors." | ( Lim, JT; Wilson, KS, 2000) |
| "We examined esophageal cancers from 138 patients to investigate whether mutational status of p53 could be correlated either with prognosis or with response to chemotherapy or radiation." | ( Furukawa, Y; Hirata, K; Kihara, C; Kimura, Y; Nakamura, Y; Seki, T; van Schaardenburgh, P; Yamana, H, 2000) |
| "Six nonoperated esophageal cancer patients were treated by daily concurrent CRT, which consisted of continuous 5-fluorouracil administration with leucovorin, combined with a low dose of daily cisplatin administration before each fraction of radiation." | ( Aoki, F; Kaminishi, M; Murakami, T; Shimoyama, S; Toyoda, K, 2000) |
| "Fifty-seven patients operated for esophageal cancer in 1997 and 1998 were treated with perioperative steroid therapy." | ( Arima, M; Funami, Y; Gunji, Y; Hayashi, H; Kobayashi, S; Matsubara, H; Miyazawa, Y; Nabeya, Y; Ochiai, T; Okazumi, S; Shimada, H; Suzuki, T; Takeda, A, 2000) |
| "Fifty-six patients with thoracic esophageal cancer infiltrating neighboring organs, but with no hematogeneous metastasis, were given preoperative concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation (40 Gy) therapy." | ( Doki, Y; Fujiwara, Y; Inoue, M; Monden, M; Shiozaki, H; Tsujinaka, T; Yano, M, 2000) |
| "Because esophageal cancer initiation by NMBA is very rapid in ZD rats, this study determined whether DFMO is effective in preventing esophageal carcinogenesis when administered after the establishment of a carcinogenic environment." | ( Fong, LY; Magee, PN; Nguyen, VT; Pegg, AE, 2001) |
| "We analyzed expression profiles of 20 esophageal cancer tissues from patients who were treated with the same adjuvant chemotherapy after removal of tumor by operation, and we attempted to find genes associated with the duration of survival after surgery." | ( Furukawa, Y; Hirata, K; Kihara, C; Kitahara, O; Nakamura, Y; Ono, K; Takagi, T; Tanaka, T; Tsunoda, T; Yamana, H; Yanagawa, R; Zembutsu, H, 2001) |
| "We report a case of advanced esophageal cancer, which was treated by chemoradiotherapy combined with surgical treatment." | ( Fukao, K; Kawamoto, T; Koike, N; Kondo, T; Moon, Y; Nakagawa, Y; Ohara, K; Shimizu, W; Todoroki, T; Yamamoto, Y; Yoshida, S, 2001) |
| "Since the therapy of advanced oesophageal cancer is unsatisfying, new therapeutic approaches are mandatory." | ( Barthel, B; Höpfner, M; Kap, H; Maaser, K; Scherübl, H; Sutter, AP; von Lampe, B; Zeitz, M, 2002) |
| "As a regional chemotherapy after esophageal cancer operation, the injection of CDDP-MS into the mediastinum for targeting of the lymph nodes thus promises to be an effective treatment." | ( Hamabe, Y; Hyon, SH; Ikuta, H; Kuroda, Y; Nakamura, Y, 2002) |
| "On the other hand, as esophageal cancer is treated mainly by surgery in Japan, CRT is applied in patients with tumors invading adjacent organs, and a high pathological complete response rate is reported in some neoadjuvant studies." | ( Hirakawa, K; Kubo, N; Matsumura, Y; Ohira, M; Yamashita, Y; Yamazaki, M, 2002) |
| "We report a patient with esophageal cancer with concomitant liver metastasis in whom complete response was achieved by chemoradiation therapy." | ( Hiramoto, J; Murakami, S; Nagayama, K; Nakada, T; Sakabe, S; Tsuruta, Y, 2002) |
| "From 1991 to 1997, 83 consecutive esophageal cancer patients underwent surgical exploration after completion of two cycles of cisplatin and 5-fluorouracil chemotherapy regimens, either in pulse or in continuous infusion cycles." | ( Chan, AC; Chung, SC; Griffith, JF; Lam, CC; Lam, YH; Lau, JY; Lee, DW; Leung, SF; Ng, EK, 2002) |
| "We reviewed salvage surgery cases for esophageal cancer following radical chemoradiotherapy." | ( Boku, N; Gotohda, N; Nagai, K; Nishimura, M; Ohtsu, A; Yoshida, J, 2002) |
| "The aim of therapy for advanced esophageal cancer is relief of dysphagia with minimal treatment-related morbidity." | ( Barr, H; Bown, SG; Dawes, RF; Eysselein, V; Giovannini, M; Harbord, M; Mishra, L; Orenberg, EK; Viens, P, 2002) |
| "A 77-year-old man with advanced esophageal cancer with tracheal and esophageal obstruction underwent continuous low-dose FP chemotherapy for a total of seven weeks, resulting in a complete response (CR) and disappearance of the esophago-tracheal fistula." | ( Hasebe, K; Sasaki, S; Takamura, H; Urade, M; Yagi, M, 2002) |
| "Recently chemoradiotherapy for esophageal cancer has been drawing public attention to the issue of quality of life maintenance for patients." | ( Endo, T; Hara, T; Hoshikawa, Y; Iino, S; Inaba, H; Kato, N; Kitajima, S; Kobayashi, Y; Koitabashi, Y; Miyazaki, A; Nakagawa, T; Nakaya, S; Ogihara, K; Tsuda, T; Watanabe, Y, 2002) |
| "The mainstay of curative treatment for oesophageal cancer is currently surgery with neoadjuvant chemotherapy or radiotherapy." | ( Anderson, MR; Jankowski, JA, 2002) |
| "Sixty-seven patients with progressive esophageal cancer treated with CRT were included in this study." | ( Fumoto, S; Mueller, W; Noguchi, T; Shibata, T; Takeno, S; Uchida, Y, 2002) |
| "The human esophageal cancer xenografts in nude mice treated by boanmycin showed morphological changes of different apoptotic phases." | ( Tang, H; Yang, XP, 2002) |
| "Thirteen patients with locally advanced esophageal cancer (T4 cases) and 3 with recurrence of esophageal cancer were treated with radiotherapy (40-70 Gy) and 5-FU combined with cisplatin/nedaplatin concurrently." | ( Kawasaki, H; Matsuya, H; Morita, T; Morohashi, H; Nakai, M; Sasaki, M; Shibata, S; Yamada, K, 2002) |
| "Among the gastrointestinal cancers, esophageal cancer is supposed to be relatively sensitive to both radiotherapy and chemotherapy." | ( Gotoh, M; Kogure, M; Terashima, M, 2002) |
| "Multimodal treatment of esophageal cancer showed promising results, although not significant, in terms of survival and disease progression for patients achieving a complete pathologic response." | ( Baccarani, U; Bresadola, F; Bresadola, V; Buffoli, A; Cartei, G; Cedolini, C; Fongione, S; Iop, A; Sacco, C; Signor, M; Terrosu, G; Uzzau, A; Vigevani, E, 2003) |
| "Treatment of Barrett's esophageal cancer is often conducted in accordance with the principles of treatment of esophageal squamous cell carcinoma, and surgical resection represents the most effective treatment." | ( Fujiwara, Y; Fukuhara, K; Kaneko, M; Kinoshita, H; Lee, S; Nishizawa, S; Osugi, H; Taguchi, S; Takemura, M; Tanaka, Y, 2003) |
| "Ninety-two patients with esophageal cancer (65 with adenocarcinoma and 27 with squamous cell carcinoma) were treated in two sequential protocols of preoperative chemoradiotherapy." | ( Burtness, B; Forastiere, AA; Heath, EI; Heitmiller, R; Kleinberg, L; Knisely, JP; Salem, R; Zahurak, M, 2003) |
| "Since mucosal (T1a) esophageal cancer is well controlled by endoscopic treatment, chemoradiotherapy (CRTx) is not indicated." | ( Fujita, H; Hayabuchi, N; Matono, S; Sasahara, H; Shirouzu, K; Sueyoshi, S; Suzuki, G; Tanaka, T; Yamana, H, 2003) |
| "Specimens of 106 patients with esophageal cancer who had pretreatment Ts/Ls staging were retrospectively studied." | ( Burrows, W; Eslami, A; Gamliel, Z; Henry, M; Ioffe, O; Jiao, X; Krasna, MJ; Kwong, KF; Refaely, Y; Zeng, Q, 2003) |
| "No effective treatment for advanced esophageal cancer extending to adjacent organs or associated with distant metastasis is known." | ( Horiuchi, Y; Indo, T; Iwase, H; Iyo, T; Kaida, S; Kato, E; Kusugami, K; Nakamura, M; Nakarai, K; Shimada, M, 2003) |
| "Treatment of human esophageal cancer KYSE 510 cells with 5-50 microM of EGCG for 12-144 h caused a concentration- and time-dependent reversal of hypermethylation of p16(INK4a), retinoic acid receptor beta (RARbeta), O(6)-methylguanine methyltransferase (MGMT), and human mutL homologue 1 (hMLH1) genes as determined by the appearance of the unmethylation-specific bands in PCR." | ( Ai, N; Fang, MZ; Hou, Z; Lu, H; Sun, Y; Wang, Y; Welsh, W; Yang, CS, 2003) |
| "However, since esophageal cancer can hardly be cured by definitive chemotherapy alone, chemotherapy plays an important role in the multimodality therapy for esophageal cancer." | ( Nabeya, Y; Ochiai, T, 2003) |
| "We report a case of esophageal cancer infiltrating the left main bronchus in which radical esophagectomy with clear surgical margins could be performed after preoperative radiochemotherapy." | ( Fujiwara, Y; Fukuhara, K; Kaneko, M; Kinoshita, H; Lee, S; Nishizawa, S; Osugi, H; Taguchi, S; Takemura, M; Tanaka, Y, 2003) |
| "Ten patients with recurrent esophageal cancer were treated with the combination of docetaxel 60 mg/m2 (day 1), CDDP 10 mg/body (days 1-5) and 5-FU 500 mg/body (days 1-5) at intervals of 2-3 weeks." | ( Fujita, H; Matono, S; Sasahara, H; Shirouzu, K; Sueyoshi, S; Tanaka, T; Yamana, H, 2003) |
| "Patients with metastatic or recurrent esophageal cancer were treated with gemcitabine 1000 mg/m(2) on days 1, 8, and 15, and cisplatin 100 mg/m(2) on day 15." | ( Abbruzzese, JL; Benedetti, JK; Chansky, K; Macdonald, JS; Pluenneke, RE; Urba, SG; VanVeldhuizen, PJ, 2004) |
| "Most patients with locally advanced esophageal cancer die from their disease, despite complete surgical extirpation of tumor or institution of aggressive, multimodality treatment." | ( Jatoi, A, 2003) |
| "For oesophageal cancer there is no effective standard therapy." | ( Giaccone, G; Kroep, JR; Peters, GJ; Pinedo, HM; Van Bochove, A; Van Groeningen, CJ, 2004) |
| "A 70-year-old patient with advanced esophageal cancer with invasion to the aorta was treated by combined chemotherapy of TS-1 and CDDP with radiotherapy." | ( Doi, R; Indou, T; Iwase, H; Iyo, T; Kaida, S; Nakarai, K; Okeya, M; Shimada, M, 2004) |
| "PBIT reduced the incidence of esophageal cancer from 96% in NMBA-treated rats to 83% and 77% (P < 0." | ( Chen, T; Kresty, LA; Nines, RG; Peschke, SM; Stoner, GD, 2004) |
| "A 51-year-old male patient with esophageal cancer and cervical, thoracic and celiac artery lymph node metastases was treated by combination chemotherapy of TS-1 and cisplatin." | ( Doi, R; Iwase, H; Kaida, S; Nakarai, K; Okeya, M; Shimada, M; Tsuzuki, T, 2004) |
| "At initial diagnosis of esophageal cancer, positron emission tomography detects more distant lymph node and organ metastases compared with conventional diagnostics, allowing a more accurate selection of the most appropriate treatment." | ( Flamen, P, 2004) |
| "Treatment of oesophageal cancer depends on staging and the general health of the patient." | ( Brink, I; Hentschel, M; Hopt, UT; Imdahl, A; Kleimaier, M, 2004) |
| "Surgery, the mainstay of treatment of esophageal cancer, has been used with neoadjuvant chemoradiotherapy to improve prognosis in patients with localized disease." | ( Dehdashti, F; Siegel, BA, 2004) |
| "After radiotherapy for advanced esophageal cancer, the survival period of the cases ranged from 14 to 22 mo, with a mean survival of 17 mo." | ( Liu, Y; Shen, BZ; Yang, G; Yu, YT, 2004) |
| "Forty patients with esophageal cancer eligible for radical esophagectomy were randomly assigned to an experimental group ( n = 20), given perioperative PGE1, or to a control group ( n = 20), given standard postoperative treatment." | ( Akiyama, S; Fujiwara, M; Ito, K; Kasai, Y; Nakao, A; Oda, K; Sakamoto, J; Sekiguchi, H, 2004) |
| "Patients with previously untreated esophageal cancer were eligible if they had performance status 0-1, were 75 years or younger and had adequate organ function." | ( Fujitani, K; Hirao, M; Tsujinaka, T, 2004) |
| "This is a report of a case with esophageal cancer in which pathological CR was obtained by neoadjvant chemoradiotherapy using a low-dose of nedaplatin (CDGP)/5-FU." | ( Fujiwara, Y; Higashino, M; Iwasaki, H; Kaneko, M; Lee, S; Nishizawa, S; Osugi, H; Takemura, M; Tanaka, Y, 2004) |
| "A 66-year-old patient, who had advanced esophageal cancer with lymph node metastasis, was treated by neoadjuvant chemo-radiotherapy, followed by curative surgery." | ( Kabashima, A; Matsusaka, T; Nishizaki, T; Ojima, Y; Sakaguchi, Y; Shimabukuro, R; Tashiro, H; Yamamoto, H; Yamamura, S, 2004) |
| "Cultured lung and esophageal cancer cells were treated with calphostin C and trichostatin A." | ( Cole, GW; Maxhimer, JB; Nguyen, DM; Reddy, RM; Schrump, DS; Zuo, J, 2005) |
| "Treatment of non operable esophageal cancer still remains debatable." | ( François, E; Lagrange, JL; Magné, N; Marcy, PY; Touati, L; Van Houtte, P, 2005) |
| "Forty-three patients with a T4 esophageal cancer were enrolled in a prospective study in which each patient decided for themselves a treatment arm, CRT-followed-by-esophagectomy or esophagectomy-followed-by-CRT." | ( Fujita, H; Hayabuchi, N; Inutsuka, H; Sasahara, H; Shirouzu, K; Sueyoshi, S; Suzuki, G; Tanaka, T; Tanaka, Y, 2005) |
| "Recently in esophageal cancer, radiation therapy has been more frequently combined with other modalities including chemotherapy and surgery." | ( Badzio, A; Jassem, J; Serkies, K, 2005) |
| "Treatment of esophageal cancer cells with smoothened antagonist, KAAD-cyclopamine, or the neutralizing antibodies of Shh reduces cell growth and induces apoptosis." | ( Adegboyega, PA; Chen, K; He, J; Huang, S; Ma, X; Sheng, T; Sultz, J; Xie, J; Zhang, H; Zhang, X; Zhang, Y, 2006) |
| "Sixty-one patients operated for esophageal cancer from 1996 to 2000 were treated postoperatively with low dose dopamine (300 microg/kg/h), gabexate mesilate (80 mg/h), and ulinastatin (300 000 unit/day) as a study group." | ( Fujii, Y; Ishiguro, H; Kimura, M; Kuwabara, Y; Sato, A; Shinoda, N, 2005) |
| "Twenty-two patients with localized esophageal cancer suitable for curative chemoradiation therapy and 24 patients suitable for palliative therapy were enrolled." | ( Burmeister, BH; Burmeister, EA; Gotley, DC; Harvey, JA; Mark Smithers, B; Thomas, J; Thomson, DB; Walpole, ET, 2005) |
| "For locally advanced esophageal cancer, the combination of esophagectomy, post-operative CCRT with weekly cisplatin and systemic adjuvant chemotherapy is well tolerated and effective." | ( Chang, CC; Chen, CC; Chen, MJ; Chen, YJ; Huang, CJ; Hung, SK; Liu, HC; Lu, LH; Tai, CJ; Tzen, CY, 2005) |
| "Data from 110 esophageal cancer patients treated between January 1998 and December 2003 were analyzed retrospectively." | ( Ajani, JA; Cox, JD; Komaki, R; Liao, Z; Liu, H; Swisher, S; Tucker, SL; Vaporciyan, AA; Wang, SL; Wei, X, 2006) |
| "We have experienced four cases of esophageal cancer treated by weekly DOC in combination with concomitant radiotherapy." | ( Ami, K; Ando, M; Nagahama, T; Ohbu, M, 2005) |
| "Fifty-two patients with resectable esophageal cancers (cT2-4, Nx, and M0) received neoadjuvant radiochemotherapy (cisplatin, 5-5-fluorouracil, 36 Gy) followed by transthoracic en bloc esophagectomy." | ( Baldus, SE; Bollschweiler, E; Brabender, J; Dienes, HP; Hoelscher, AH; Ling, FC; Metzger, R; Moenig, S; Mueller, RP; Neiss, S; Schneider, PM; Warnecke-Eberz, U; Xi, H, 2005) |
| "Treatment of esophageal cancer cells with 5-Fu and cisplatin induced NF-kappaB and AP-1 activation." | ( Abdel-Latif, MM; Kelleher, D; Raouf, AA; Reynolds, JV; Sabra, K, 2005) |
| "This study is the first to evaluate esophageal cancer treatment with a pharmacogenetic paradigm and its application of pharmacogenetic analysis to multiple genes in each drug action pathway as a means of developing a more accurate and consistent risk prediction model." | ( Ajani, JA; Chiang, SS; Lu, C; Wu, X, 2005) |
| "Our data suggest that esophageal cancers with activated NF-kappaB have aggressive clinical biology and poor treatment outcome." | ( Aggarwal, BB; Ajani, JA; Chao, KS; Ensor, J; Hittelman, WN; Izzo, JG; Lee, JH; Liao, Z; Luthra, R; Malhotra, U; Swisher, SG; Wu, TT, 2006) |
| "Multimodality therapy for esophageal cancer holds promise for improving outcome in this lethal disease." | ( Beard, M; Cheng, JD; Freedman, G; Goldberg, M; Henry, LR; Konski, A; McLaughlin, S; Meropol, NJ; Scott, W; Watts, P; Weiner, LM, 2006) |
| "Human esophageal cancers have been shown to express high levels of epidermal growth factor receptor (EGFR) and a relationship between high EGFR expression and local advance, the number of lymph node metastases, life expectancy, and sensitivity to chemo-radiotherapy has been demonstrated." | ( Doihara, H; Hara, F; Ishibe, Y; Oota, T; Shien, T; Shimizu, N; Taira, N; Takahashi, H; Yoshitomi, S, 2006) |
| "Twenty-one patients operated on for oesophageal cancer in 2003-2004 were treated with perioperative steroid therapy (250 mg of methylprednisolone intravenously 1 h before the operation)." | ( Fukai, Y; Fukuchi, M; Katoh, H; Kimura, H; Kuwano, H; Manda, R; Masuda, N; Miyazaki, T; Nakajima, M; Sohda, M; Tsukada, K, 2006) |
| "Approximately 25% of esophageal cancer patients experience a pathologic complete response (pCR) to preoperative chemoradiation therapy." | ( Blackstock, AW; Clark, P; Farmer, MR; Geisinger, KR; Ho, C; Levine, EA; Lovato, J; Melin, SA; Mishra, G; Oaks, T, 2006) |
| "Patients with advanced esophageal cancer, who had failed one line of prior chemotherapy, were administered gefitinib 500 mg/d." | ( Gallegos-Ruiz, MI; Giaccone, G; Janmaat, ML; Meijer, GA; Richel, DJ; Rodriguez, JA; Van Groeningen, C; Vervenne, WL, 2006) |
| "We report a patient with advanced esophageal cancer who achieved a complete response to combination chemotherapy of TS-1, docetaxel and CDDP." | ( Kitakata, H; Omote, K; Takahashi, Y; Yamashita, K; Yasumoto, K, 2006) |
| "Early identification of esophageal cancer patients who are responding or resistant to combined chemoradiotherapy may lead to individualized therapeutic approaches and improved clinical outcomes." | ( Ajani, JA; Alauddin, MM; Apisarnthanarax, S; Ariga, H; Bornmann, WG; Chao, KS; Gelovani, JG; Han, D; Mawlawi, O; Milas, L; Mourtada, F; Raju, U, 2006) |
| "Patients with no prior treatment and oesophageal cancer stage I to III, performance status <3, caloric intake >1,500 kcal day(-1) were included." | ( Adenis, A; Boucher, E; Dahan, L; Di Fiore, F; Galais, MP; Hamidou, H; Hellot, MF; Jacob, JH; Michel, P; Mirabel, X; Paillot, B; Prod'homme, S; Raoul, JL, 2006) |
| "Thirty-two patients with localised oesophageal cancer had a pretreatment PET scan and a repeat after the first week of chemoradiation." | ( Duffy, GJ; Gillham, CM; Hollywood, D; Keogan, M; Lucey, JA; Malik, V; Muldoon, C; O'byrne, K; Raouf, AA; Reynolds, JV, 2006) |
| "The major aims of imaging in esophageal cancer are to distinguish between locoregional and systemic disease (M-stage), to determine local tumor extension (T- and N-stage), to assess response to chemo- or chemoradiotherapy and to identify recurrence of cancer." | ( Ott, K; Siewert, JR; Weber, W, 2006) |
| "In total, 28 patients with recurrent esophageal cancer after the initial treatment (esophagectomy, chemotherapy and/or chemoradiotherapy) were enrolled." | ( Aoki, T; Hoshino, S; Osaka, Y; Tachibana, S; Takagi, Y; Tsuchida, A, 2006) |
| "Neoadjuvant treatment modalities for esophageal cancer were developed to improve local tumor control as well as to reduce lymph node metastases and distant metastases in patients with locally advanced esophageal cancer." | ( Baldus, SE; Bollschweiler, E; Dienes, HP; Hölscher, AH; Izbicki, JR; König, A; Mueller, RP; Prenzel, KL; Schneider, PM; Schnickmann, C; Schröder, W, 2007) |
| "The major aims of imaging in esophageal cancer are to determine local tumor extension (T and N staging), to rule out systemic disease (M staging), and to assess response to neoadjuvant therapy (response evaluation)." | ( Beer, AJ; Hannig, C; Holzapfel, K; Rummeny, EJ, 2007) |
| "He was diagnosed as having esophageal cancer of stage IVa (T2N4M0) in October, 2002, and he received chemoradiotherapy (nedaplatin (CDGP)/5-fluorouracil (5-FU) total 6 course+60 Gy)." | ( Chinen, T; Fujita, J; Hirata, T; Hokama, A; Kinjo, F; Kinjo, N; Nakachi, N; Nakamoto, M; Uchima, N; Watanabe, T, 2007) |
| "The data from 36 patients treated for esophageal cancer with thoracic radiotherapy who underwent restaging PET/CT imaging between 4 and 12 weeks after radiotherapy completion were evaluated." | ( Ajani, J; Guerrero, T; Hart, J; Johnson, V; Khan, M; Komaki, R; Liao, Z; Luo, D; Pan, T; Stevens, C, 2007) |
| "Thirty-four oesophageal cancer patients with co-morbid medical conditions, locally advanced tumours (T4) or advanced age (older than 75 years) received docetaxel (20 mg/m2 weekly) plus concurrent radiotherapy (2 Gy daily, to a total dose of 66 Gy)." | ( Abad, A; Arellano, A; Boix, J; Cardenal, J; Casas, D; Fernández-Llamazares, J; Font, A; Manzano, JL; Margelí, M; Rosell, R, 2007) |
| "Since esophageal cancer has often metastasized at the time of diagnosis, current treatment modalities offer poor survival and cure rates." | ( Chen, T; Stoner, GD; Wang, LS, 2007) |
| "Patients with local/regional oesophageal cancer with adequate functional status should not be excluded from potentially curative treatment based on age alone." | ( Anderson, SE; Bains, M; Hummer, A; Ilson, DH; Kelsen, D; Minsky, BD, 2007) |
| "For patients with localized esophageal cancer, whether or not preoperative chemotherapy is administered, only an R0 resection results in substantial long-term survival." | ( Ajani, JA; Estes, NC; Gunderson, LL; Haller, DG; Kelsen, DP; Kocha, W; Minsky, BD; Mortimer, J; Roth, JA; Willett, CG; Winter, KA, 2007) |
| "The incidence of oesophageal cancer (OC) has risen in recent decades, with survival rates remaining poor despite surgical treatment and adjuvant chemotherapy." | ( Deasy, BM; McKenna, SL; O'Donovan, TR; O'Sullivan, GC; O'Sullivan-Coyne, G, 2007) |
| "Locally advanced esophageal cancer is challenging to treat." | ( Alberts, SR; Fitch, TR; Foster, NR; Jatoi, A; Lair, BS; Martenson, JA; McLeod, HL; Moore, DF; Nichols, F; Tschetter, LK, 2007) |
| "Patients with esophageal cancer often develop metastatic disease after esophageal resection and generally receive cisplatin-based chemotherapy or chemoradiotherapy." | ( Fujita, H; Mori, N; Nagano, T; Sasahara, H; Shirouzu, K; Sueyoshi, S; Tanaka, T; Tanaka, Y; Yamana, H, 2007) |
| "Twenty patients with metastatic esophageal cancer after esophagectomy refractory to cisplatin-based therapy were included in this study." | ( Fujita, H; Mori, N; Nagano, T; Sasahara, H; Shirouzu, K; Sueyoshi, S; Tanaka, T; Tanaka, Y; Yamana, H, 2007) |
| "Six patients with recurrent esophageal cancer after external radiotherapy were treated with HDR brachytherapy (Ir-192 source) from January 2003 to February 2004." | ( Hirata, H; Honda, H; Nakamura, K; Nonoshita, T; Sasaki, T; Shioyama, Y; Toh, Y, 2007) |
| "Patients with stage I or II esophageal cancer received preoperative radiation therapy (28-30 daily 1." | ( Adenis, A; Lartigau, E; Mariette, C; Mirabel, X; Sarrazin, T; Triboulet, JP, 2008) |
| "Twenty-six patients with distal esophageal cancer who received chemoradiotherapy before esophagectomy were included." | ( Balachandran, A; Bruzzi, JF; Iyer, RB; Johnson, V; Macapinlac, HA; Munden, RF, 2007) |
| "All cervical esophageal cancer patients treated between 1997 and 2005 were restaged (1983 American Joint Committee on Cancer criteria)." | ( Bayley, A; Brierley, J; Cummings, B; Huang, SH; Kim, J; Lockwood, G; Ringash, J; Wong, R, 2008) |
| "In locally advanced esophageal cancer it has been proved that the definitive radiochemotherapy is an alternative at radiochemotherapy plus surgery." | ( Di Fiore, F; Michel, P, 2008) |
| "In patients with advanced esophageal cancer, treatment with an esophageal stent loaded with (125)I seeds, compared with that with a conventional covered stent, has potential benefit in that it allows a slightly longer relief of dysphagia and extended survival." | ( Deng, G; Fang, W; Guo, JH; He, SC; Li, GZ; Teng, GJ; Zhu, GY, 2008) |
| "A 64-year-old woman with advanced esophageal cancer underwent chemotherapy with docetaxel/5-FU/CDDP (DFP)." | ( Honda, J; Matsuoka, H; Miyoshi, T; Seike, J; Tangoku, A; Yamai, H; Yoshida, T; Yuasa, Y, 2008) |
| "Between 1998 and 2004, 66 esophageal cancer patients with adjuvant chemotherapy and 160 well-matched patients without chemotherapy were included in this study." | ( Chen, ZW; Hu, H; Lu, S; Luo, QQ; Ma, LF; Miao, LS; Xiang, JQ; Zhang, J; Zhang, YW; Zhou, XY, 2008) |
| "In 71 patients with esophageal cancer who underwent neoadjuvant chemotherapy (cisplatin, adriamycin and 5-fluorouracil) followed by surgery, plasma d-dimer levels were measured before chemotherapy and the clinical and pathological responses to chemotherapy were assessed at 4 weeks after therapy (after surgery)." | ( Imaoka, S; Ishikawa, O; Kishi, K; Miyashiro, I; Ohigashi, H; Ohue, M; Sasaki, Y; Takachi, K; Tomimaru, Y; Yano, M, 2008) |
| "The treatment of choice for esophageal cancer is considered surgical resection, but a median survival of around 20 months after treatment is still discouraging." | ( Bulut, D; Chromik, AM; Daigeler, A; Geisler, A; Hilgert, C; Klein-Hitpass, L; Krieg, A; Lehnhardt, M; Mittelkötter, U; Uhl, W, 2008) |
| "DCE-MRI is feasible in patients with esophageal cancer, reveals therapeutic effects, and may thus be useful in therapy management and monitoring." | ( Düber, C; Junginger, T; Kunz, P; Mildenberger, P; Oberholzer, K; Pohlmann, A; Schmidberger, H; Schreiber, W, 2008) |
| "Fifty-two esophageal cancer patients undergoing FDG-PET as part of initial routine staging procedure before treatment were included." | ( Cheze-Le Rest, C; Jestin-Le Tallec, V; Lozac'h, P; Metges, JP; Teyton, P; Visvikis, D; Volant, A, 2008) |
| "Patients with localized esophageal cancer (LEC) have diverse outcomes (post-therapy pathologic response, disease-free survival [DFS], and overall survival [OS]) after preoperative chemoradiation (P-CTRT), dictated also by inherent molecular heterogeneity." | ( Ajani, JA; Arora, R; Bhutani, MS; Correa, AM; Hofstetter, WL; Izzo, JG; Javeri, H; Lee, JH; Liao, Z; Maru, D; McAleer, MF; Swisher, SG, 2008) |
| "Treatment of oesophageal cancer cell lines with 5-aza-2'-deoxycytidine and trichostatin-A led to reversal of the methylation pattern and re-expression of these genes at the mRNA and protein levels." | ( Chen, H; El-Rifai, W; Peng, DF; Razvi, M; Roessner, A; Schneider-Stock, R; Washington, K, 2009) |
| "We present a case of esophageal cancer with multiple lymph node metastases successfully performed early response evaluation for preoperative chemotherapy by FDG-PET." | ( Arakaki, K; Isa, T; Kaneshiro, T; Nakachi, A; Nishimaki, T; Shiroma, H; Teruya, T; Yamamoto, H, 2008) |
| "Ten patients with gastro-oesophageal cancer referred for radiation therapy underwent both (18F)fluoro-2-deoxy-d-glucose-PET (FDG-PET) and computed tomography in the treatment position." | ( Breen, S; Brock, K; Cheung, F; Darling, G; Dinniwell, R; Grabarz, D; Haider, M; Kamra, J; Knox, J; Mah, K; Mansouri, A; Pond, G; Ung, Y; Vesprini, D; Wong, RK, 2008) |
| "Fourteen patients with localised oesophageal cancer suitable for curative chemoradiation therapy registered on the study." | ( Burmeister, BH; Burmeister, EA; Cox, S; D'Arcy, N; Harvey, JA; Smithers, BM; Thomson, DB; Walpole, ET, 2009) |
| "Early detection of esophageal cancer in patients with head and neck cancers may alter treatment planning and improve survival." | ( Chen, CC; Chiu, HM; Hsiu-Hsi Chen, T; Huang, HY; Ko, JY; Lee, YC; Lin, JT; Lou, PJ; Wang, CP; Wang, HP; Wu, MS; Yang, TL, 2009) |
| "We report here a case of esophageal cancer patient who developed tumor lysis syndrome after chemotherapy." | ( Nishimura, T; Oka, M; Takeda, S; Tokunou, K; Yoshino, S, 2008) |
| "In patients with esophageal cancer who receive chemoradiation, tools to predict/prognosticate outcome before administering therapy are lacking." | ( Ajani, JA; Bhutani, MS; Hofstetter, W; Javeri, H; Komaki, R; Lee, JH; Maru, D; Rohren, E; Swisher, SG; Wang, X; Xiao, L, 2009) |
| "Among the 65 patients with advanced esophageal cancer, 27 had no history of prior chemotherapy and the other 38 had ever received postoperative adjuvant chemotherapy before." | ( Chen, XB; Fan, QX; Geng, L; Han, JW; Jiao, ZM; Lu, P; Lu, SP; Lu, TY; Luo, SX; Ma, ZY; Song, M; Wang, GJ; Wang, JS; Wang, R; Wang, RL; Wu, XA; Zhang, MZ; Zhao, YF, 2008) |
| "In patients with locally advanced esophageal cancer, preoperative chemotherapy or chemoradiotherapy has been shown to improve outcome with respect to survival." | ( Herrmann, K; Krause, BJ; Wieder, H; zum Büschenfelde, CM, 2009) |
| "A xenograft model using SCID mice with esophageal cancer cells would monitor gene changes during treatment and regrowth." | ( Miyoshi, T; Seike, J; Takechi, H; Tangoku, A; Yamai, H; Yoshida, T; Yuasa, Y, 2009) |
| "Anderson Cancer Center for esophageal cancer and who had undergone [(18)F]-fluorodeoxyglucose positron emission tomography/computed tomography between November 1, 2003 and December 15, 2007 for disease restaging after chemoradiotherapy." | ( Ajani, J; Baker, J; Ezhil, M; Guerrero, T; Johnson, V; Khan, M; Luo, D; McAleer, MF; McCurdy, M; Wei, W, 2010) |
| "One patient with esophageal cancer and one with gastric cancer treated with RAD001 at 10 mg/day showed marked tumor responses." | ( Doi, T; Kobayashi, K; Kurei, K; Miyazaki, M; Nakagawa, K; Ohtsu, A; Okamoto, I; Tsuya, A, 2010) |
| "Sixty inpatients with advanced esophageal cancer from Henan Tumor Hospital, and the Fist Affiliated Hospital of Zhengzhou University were included and randomly divided into treatment group and control group." | ( Fan, QX; Huang, JY; Sun, Y; Zhang, YQ, 2009) |
| "The standard chemotherapy regimen for esophageal cancer is cisplatin and 5-fluorouracil (5-FU)." | ( Oka, M; Takeda, S; Tsutsui, M; Watanabe, Y; Yoshino, S, 2009) |
| "We have experienced a case of advanced esophageal cancer that has come back eight years after combined modality therapy, and after that, the patient could obtain a long-term survival with a marked effect of chemotherapy." | ( Aoyama, N; Minamide, J; Ota, Y; Takata, K, 2009) |
| "In patients with advanced gastric and esophageal cancer who were not candidates for every-3-week DCF, a weekly formulation of DCF demonstrated modest activity with minimal hematologic toxicity, suggesting that weekly DCF is a reasonable treatment option for such patients." | ( Abbruzzese, JL; Ajani, J; Ho, L; Jhamb, J; Kazmi, SM; Lin, E; Overman, MJ; Phan, A; Yao, JC, 2010) |
| "Patients with deeply invading (T3-T4) oesophageal cancers usually receive chemoradiotherapy with or without surgery." | ( Doki, Y; Fujiwara, Y; Miyata, H; Mori, M; Nakajima, K; Takiguchi, S; Yamasaki, M, 2010) |
| "In this patient, esophageal cancer associated with Fanconi anemia responded well to multidisciplinary therapy." | ( Hirashima, Y; Hosoya, Y; Jinbu, Y; Lefor, A; Muroi, K; Nakazawa, M; Nokubi, M; Yamaguti, T; Yasuda, Y, 2010) |
| "We treated esophageal cancer cells with BPDE before performing methylation-specific polymerase chain reaction (MSP) to find that BPDE induced methylation of the RAR-beta2 gene promoter." | ( Xu, XC; Ye, F, 2010) |
| "In our hospital, 348 patients with esophageal cancer received chemotherapy consisting of nedaplatin and 5-fluorouracil and concurrent irradiation." | ( Ise, M; Kumagai, K; Mimura, N; Nagata, M; Sakai, C; Takagi, T; Tsujimura, H, 2010) |
| "Five paired samples from oesophageal cancer patients before and after chemotherapy were analysed using the same methodology." | ( Appleyard, V; Baker, L; Exon, D; Kelly, P; Lamont, D; Murray, K; Paulin, F; Suttie, S; Thompson, A, 2010) |
| "Between 1997 and 2007, 94 patients with esophageal cancer were treated with chemoradiation in our institute." | ( Aleman, BM; Boot, H; Cats, A; Courrech Staal, EF; Jansen, EP; van Coevorden, F; van Sandick, JW; van Velthuysen, ML, 2011) |
| "For most patients with esophageal cancer, esophagectomy is an effective therapy." | ( Hu, Y; Xie, T; Yuan, Y; Zhao, Y, 2010) |
| "Untreated stage II-IVa esophageal cancer patients with performance status 0-2 were included." | ( Ansari, RH; Choong, NW; Ferguson, MK; Fishkin, PA; Haraf, DC; Hoffman, PC; Kesler, KA; Kocherginsky, M; Krauss, SA; Mauer, AM; Posner, MC; Sandler, AB; Sciortino, DF; Szeto, L; Vokes, EE; Wade, J, 2011) |
| "Curative treatment of esophageal cancer with definitive or preoperative high-dose chemoradiotherapy inflicts a major strain on the patients with potentially severe physical, emotional, and social consequences." | ( Aarstad, AK; Aarstad, HJ; Hjermstad, MJ; Hurmuzlu, M; Viste, A, 2011) |
| "A 77-year-old male with thoracic esophageal cancer (cT3N3M0, Stage III) received nedaplatin at 80mg/m2 for 1 day and 5-fluorouracil at 800mg/m2 for 5 days as neoadjuvant treatment." | ( Gyobu, K; Hashiba, R; Isohata, N; Iwasaki, H; Kishida, S; Lee, S; Matsuda, Y; Mori, K; Osugi, H, 2010) |
| "A 72-year-old man with esophageal cancer who could not sit down or stand up was administered 5 mg/day haloperidol to relieve agitation as a symptom of major depressive disorder." | ( Ishida, M; Ito, H; Kawanishi, C; Mizuno, K; Narabayashi, M; Onishi, H; Sasaki, Y; Wada, M; Wada, T, 2010) |
| "To improve the prognosis of advanced esophageal cancer, neoadjuvant chemotherapy (NACT) followed by surgery is a promising treatment strategy." | ( Doki, Y; Fujiwara, Y; Komori, T; Matsubara, K; Matsuura, N; Miyata, H; Monden, M; Mori, M; Motoori, M; Takemasa, I; Takeno, A; Takiguchi, S; Yamasaki, M; Yano, M; Yasuda, T, 2010) |
| "Treatment options for localized gastroesophageal cancers reach from limited resection to multimodality treatment." | ( Krause, BJ; Lordick, F; Ott, K, 2010) |
| "Chemoradiotherapy (CRT) for esophageal cancer is disadvantageous because of a high locoregional failure rate." | ( Horimatsu, T; Ishikura, S; Minashi, K; Muto, M; Nihei, K; Ohtsu, A; Onozawa, M; Taku, K; Tu, CH; Yano, T; Yoshida, S, 2011) |
| "Locally advanced oesophageal cancer (LAEC) is associated with poor survival and more effective treatments are needed." | ( Day, FL; Di Iulio, J; Jefford, M; Leong, T; Matera, A; McKendick, J; Michael, M; Milner, AD; Ngan, S; Rischin, D; Thomas, R; Zalcberg, JR, 2011) |
| "A total of 8 esophageal cancer patients with relapsed mediastinal lymph nodes (6 patients), psychological disease (1 patient) and local advanced tumor (cT4) after initial 5-FU/CDDP therapy (1 patients) received docetaxel (10 mg/m2 weekly) plus concurrent radiotherapy (2 Gy daily, a total dose of 60 Gy)." | ( Amano, R; Hirakawa, K; Ishikawa, T; Kubo, N; Maeda, K; Morimoto, J; Muguruma, K; Nagahara, H; Nakata, B; Noda, E; Ohira, M; Onoda, N; Sakurai, K; Sawada, T; Takashima, T; Tanaka, H; Yamada, N; Yashiro, M, 2010) |
| "We present a case of advanced esophageal cancer with multiple lymph node metastases successfully treated by combination therapy of docetaxel, cisplatin and 5-FU (DCF) followed by salvage lymphadenectomy." | ( Kanemura, T; Kobayashi, M; Miki, H; Nakahira, S; Nakata, K; Okamura, S; Ono, H; Suzuki, R; Takeda, Y; Takeno, A; Tamura, S; Uchiyama, C; Yanai, A; Yoshioka, Y, 2010) |
| "We report here a case of recurrent esophageal cancer successfully treated by cervical lymph node dissection and chemo-radiation therapy." | ( Andoh, S; Kitamura, Y; Tokunou, K; Toshimitsu, H; Tsushimi, K; Yamamoto, T, 2010) |
| "This chemotherapy reduced the esophageal cancer mass significantly, and subtotal esophagectomy was performed." | ( Hamatsu, T; Hasegawa, H; Honboh, T; Kabashima, A; Kitamura, M; Kudo, K; Ninomiya, M; Ushijima, C, 2010) |
| "Forty-one patients with newly diagnosed esophageal cancer treated with combined radiochemotherapy were included in this study." | ( Albarghach, N; Corcos, L; Hatt, M; Le Rest, CC; Metges, JP; Pradier, O; Tixier, F; Visvikis, D, 2011) |
| "A total of 43 patients with esophageal cancer, who were candidates for esophagectomy (without neo-adjuvant chemotherapy), were enrolled in this study from 2007 to 2009." | ( Bagheri, R; Maddah, G; Roodbari, S; Sadeghian, MH; Saedi, HS, 2011) |
| "Advanced esophageal cancer with widespread metastasis to lymph nodes or other organs is difficult to treat and has an extremely poor prognosis." | ( Aoki, T; Hoshino, S; Ogata, T; Osaka, Y; Shinohara, M; Takagi, Y; Tsuchida, A, 2011) |
| "Fifty patients with oesophageal cancer treated with concomitant radiochemotherapy between 2004 and 2008 were retrospectively considered and classified as complete, partial or non-responders (including stable and progressive disease) according to Response Evaluation Criteria in Solid Tumors (RECIST)." | ( Cheze-le Rest, C; Hatt, M; Pradier, O; Visvikis, D, 2011) |
| "Recent data in esophageal cancer suggests the variant allele of a single-nucleotide polymorphism (SNP) in XRCC1 may be associated with resistance to radiochemotherapy." | ( Benson, AB; Catalano, PJ; Forastiere, AA; Gibson, MK; Hafez, MJ; Kleinberg, LR; Liu, G; Meltzer, SJ; Montgomery, EA; Murphy, KM; Offer, SM; Philips, S; Powell, M; Skaar, TC; Wu, X; Yoon, HH, 2011) |
| "Treatment of esophageal cancer cell lines with the phorbol ester phorbol 12,13 dibutyrate led to a rapid and dramatic increase in the activation of protein kinase D." | ( Carballo, M; Maish, MS; Yetasook, A, 2011) |
| "A total of 139 esophageal cancer patients treated with CCRT (cisplatin-based chemotherapy combined with 40 Gy of irradiation) and subsequent esophagectomy were recruited at the National Taiwan University Hospital between 1997 and 2008." | ( Chen, PC; Chen, SK; Chen, YC; Chuang, EY; Hsiao, CK; Lai, LC; Lee, JM; Lee, YC; Tsai, MH; Yang, PW, 2012) |
| "Because most esophageal cancers are diagnosed at an advanced stage, a majority of patients require palliative dysphagia treatment." | ( Butruk, E; Fijuth, J; Kraszewska, E; Polkowski, M; Regula, J; Rupinski, M; Wronska, E; Zagorowicz, E, 2011) |
| "In patients with inoperable esophageal cancer, palliative combination treatment of dysphagia with APC and HDR or PDT was significantly more efficient than APC alone, and was safe and well tolerated." | ( Butruk, E; Fijuth, J; Kraszewska, E; Polkowski, M; Regula, J; Rupinski, M; Wronska, E; Zagorowicz, E, 2011) |
| "CR to CRT for the esophageal cancer and CR to chemotherapy for the gastric cancer were achieved." | ( Fujii, M; Funada, T; Kaiga, T; Kanamori, N; Kochi, M; Mihara, Y; Takayama, T; Tamegai, H; Watanabe, M; Yoshida, N, 2011) |
| "Twenty patients with advanced esophageal cancer who underwent cisplatin-based neoadjuvant chemotherapy were enrolled in a prospective observational study." | ( Doki, Y; Fujiwara, Y; Hiura, Y; Kurokawa, Y; Miyata, H; Mori, M; Nakajima, K; Takiguchi, S; Yamamoto, K; Yamasaki, M, 2012) |
| "A total of 104 patients with advanced esophageal cancer received 2 courses of NAF-chemotherapy between February 2003 and March 2010." | ( Fujitani, K; Hasegawa, H; Hirao, M; Mita, E; Nakazuru, S; Tsujinaka, T, 2011) |
| "Fifteen patients with esophageal cancer received chemotherapy, six of whom had grade one oral mucositis." | ( Fukui, T; Itoh, Y; Kawada, S; Orihara, M; Takeda, H; Yoshioka, T; Yoshizawa, K, 2011) |
| "A positive effect of MSH on esophageal cancer has been demonstrated, however, there is no study on the in vitro effects of heating treatment or of the effects of AMF exposure on human esophageal cancer cells." | ( Li, DY; Li, LY; Liu, JY; Tang, JT; Tao, D; Wang, YY; Zhao, LY, 2012) |
| "We report a rare case of esophageal cancer resection in which lung metastases was resected after chemotherapy with paclitaxel." | ( Inoue, S; Miyata, M; Ohashi, I; Takami, K; Tamura, C; Wakasa, T, 2011) |
| "Fifty patients with esophageal cancer treated with concomitant radiochemotherapy between 2004 and 2008 were retrospectively considered." | ( Cheze Le Rest, C; Hatt, M; Le Pogam, A; Pradier, O; Visvikis, D, 2012) |
| "The prevalence of esophageal cancer during the pretreatment of HPC patients was 51." | ( Kawano, T; Kishimoto, S; Makino, T; Nakaminato, S; Shibuya, H; Toriihara, A, 2012) |
| "For cT2 N0 esophageal cancer patients, the benefit of neoadjuvant therapy is still unclear." | ( Brock, MV; Franco, N; Hooker, CM; How, R; Hulbert, A; Lee, S; Prevas, H; Shin, J; Yang, SC; Zhang, JQ, 2012) |
| "Forty-two patients with esophageal cancer who were receiving cisplatin-based neoadjuvant chemotherapy were assigned to either a ghrelin group (n = 21) or a placebo group (n = 21)." | ( Doki, Y; Fujiwara, Y; Hiura, Y; Kangawa, K; Kurokawa, Y; Miyata, H; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamamoto, K; Yamasaki, M, 2012) |
| "Current chemotherapy for esophageal cancer is conducted on the basis of empirical information from clinical trials, which fails to take into account the known heterogeneity of chemosensitivity between patients." | ( Fang, XH; Gu, LH; Ling, ZQ; Lu, XX; Mao, WM; Qi, CJ; Qian, LJ; Wang, S; Yang, ZX; Yin, J; Zhao, Q; Zheng, ZG, 2012) |
| "One hundred and sixty eight patients of esophageal cancer were randomly divided into 3 groups, including the radiotherapy alone group (CF) which received conventional conformal radiotherapy to a total of 60 - 66 Gy, LCAF group which received conventional fractionated conformal radiotherapy during the first two-thirds of the treatment to a dose about 40 Gy/20F/4W, then followed by late accelerated hyperfractionated conformal radiotherapy, twice daily radiotherapy at 1." | ( Feng, XZ; Han, JQ; Sheng, W, 2011) |
| "Concurrent chemoradiotherapy for esophageal cancer impairs LVF from an early treatment stage." | ( Hatakenaka, M; Higo, T; Honda, H; Kamitani, T; Matsuo, Y; Nagao, M; Nakamura, K; Nishikawa, K; Nonoshita, T; Setoguchi, T; Shioyama, Y; Yabuuchi, H; Yonezawa, M, 2012) |
| "In this study, patients with oesophageal cancer were divided into two group: one with neoadjuvant therapy and the other without neoadjuvant therapy." | ( Asnaashari, A; Bagheri, R; Ghazvini, K; RajabiMashhadi, MT; Sahebi, MA; Zahediyan, A, 2012) |
| "Treatment options for oesophageal cancer have changed considerably over the last decades with the introduction of multimodal treatment concepts dominating the progress in the field." | ( Belka, C; Hölzel, D; Schmidt, M; Wolf, MC; Zehentmayr, F, 2012) |
| "By this stage of esophageal cancer, surgery, although very invasive, is the standard radical therapy for the patients." | ( Kameda, Y; Ohkawa, S; Tamai, S; Yoshii, T, 2013) |
| "The treatment results for cT4 esophageal cancer were examined in 81 patients who received definitive CRT [radiation 50-70 Gy, cisplatin and 5-fluorouracil; group I] and 19 patients who underwent esophagectomy after preoperative CRT [40Gy, Group II]." | ( Ikeda, Y; Maehara, S; Maehara, Y; Minami, K; Morita, M; Ohgaki, K; Okamura, T; Saeki, H; Sakaguchi, Y; Sugiyama, M; Toh, Y; Uehara, S, 2012) |
| "In patients treated for an esophageal cancer, the present study suggested that 18F-fluorodeoxyglucose-positron emission tomography after chemoradiotherapy completion was an independent prognostic factor of overall survival without significant impact on local recurrence prediction." | ( Benyoucef, A; Blondin, V; Di Fiore, F; Edet-Sanson, A; Hitzel, A; Huet, E; Michel, P; Vera, P, 2012) |
| "Eighty patients with esophageal cancer were enrolled in the study between January, 2004 and December, 2007, who were randomly divided into two groups of 40, one of which was treated with hand-video-assisted thoracoscopy surgery (HVATS) esophagectomy and one of which was treated with conventional surgery." | ( Dong, W; Du, J; Li, X; Meng, L; Ni, Y; Shen, H; Wang, G, 2012) |
| "HAI can be a treatment of choice for esophageal cancer when metastasis is limited to the liver." | ( Hasegawa, H; Ikebe, M; Kitamura, M; Saitoh, G, 2012) |
| "We retrospectively studied 100 esophagus cancer patients treated with proton therapy." | ( Bernard, V; Buckley, W; Castillo, E; Castillo, R; Echeverria, AE; Guerrero, T; Liu, P; Martinez, J; McCurdy, M; Ramos, NV, 2013) |
| "Twenty patients with esophageal cancer were treated with trimodal therapy (CRT plus surgery) and underwent [(18)F]FDG-PET/CT scans both before (pre-CRT) and after (post-CRT) CRT." | ( Chen, W; D'Souza, WD; Feigenberg, S; Kim, G; Kligerman, S; Lu, M; Lu, W; Suntharalingam, M; Tan, S, 2013) |
| "One-hundred and twenty patients with esophageal cancer treated by an association of radiotherapy and chemotherapy and possibly surgery, between 2004 and 2010, were retrospectively studied." | ( Capitain, O; Cellier, P; Denis, F; Girault, S; Hamy, A; Mahé, MA; Mesgouez-Nebout, N; Paumier, A; Poirier, AL; Rousseau, D, 2013) |
| "Fourteen patients with esophageal cancer were enrolled and received DNF combination therapy at different dose levels according to the treatment and examination plan." | ( Fukuchi, M; Ieta, K; Inose, T; Kato, H; Kuwano, H; Miyazaki, T; Nakajima, M; Ojima, H; Sakai, M; Sano, A; Sohda, M; Suzuki, S; Tanaka, N; Yokobori, T, 2013) |
| "Patients with stage IVA esophageal cancer treated with chemoradiotherapy between April 2003 and March 2009 were evaluated." | ( Anbai, A; Hashimoto, M; Jin, M; Koga, M; Motoyama, S; Shibata, H, 2013) |
| "We enrolled 56 patients with esophageal cancer treated with definitive CRT and examined by FDG-PET before treatment." | ( Abe, K; Asai, K; Atsumi, K; Baba, S; Hirakawa, M; Honda, H; Isoda, T; Nakamura, K; Ohga, S; Sasaki, T; Shinoto, M; Shioyama, Y; Yoshitake, T, 2013) |
| "The survival rates of esophageal cancer treated with DCRT in North West of Iran is poor; therefore, early detection and improved treatment methods, with clinical trials are a high priority." | ( Ghojazadeh, M; Jangjoo, AG; Mirinezhad, SK; Mohammadzadeh, M; Naseri, AR; Nasiri, B; Seyednezhad, F; Somi, MH, 2013) |
| "Elderly patients with esophageal cancer who are not candidates for chemoradiation may benefit from targeted agents; hence erlotinib combined with radiotherapy was evaluated in this trial." | ( Chhatrala, R; Iyer, R; Khushalani, N; Levea, C; Malhotra, U; Robins, M; Shefter, T; Tan, W; Yang, G, 2013) |
| "We retrospectively studied 276 esophageal cancer patients treated with nCRT and surgery between 2002 and 2008." | ( Chan, SC; Chang, HK; Chao, YK; Chen, WH; Chiu, CH; Liu, YH; Tseng, CK, 2013) |
| "DNA from 143 esophageal cancer patients, 63 receiving neoadjuvant therapy and 80 receiving primary surgery, was analyzed for the following polymorphisms: the GSTM1 null, GSTT1 null, and GSTP1 Ile105Val (rs16953) in glutathione S-transferase (GST) family, 2 in thymidylate synthase (TS) gene, and the ERCC1 Asn118Asn (rs11615), ERCC1 C8092A (rs3212986), XPD/ERCC2 Asp312Asn (rs1799793), and XPD/ERCC2 Lys751Gln (rs13181) of the nucleotide excision repair pathway." | ( Alfieri, R; Amadori, A; Ancona, E; Basso, D; Boldrin, E; Cagol, M; Castoro, C; Cavallin, F; Rumiato, E; Ruol, A; Saggioro, D, 2013) |
| "Consecutive patients with oesophageal cancer who underwent neoadjuvant chemotherapy followed by surgery were studied." | ( Doki, Y; Kurokawa, Y; Miyata, H; Mori, M; Murakami, K; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M, 2013) |
| "Twenty patients with esophageal cancer treated with CRT plus surgery were included in this study." | ( Chen, W; D'Souza, WD; Lu, W; Tan, S; Zhang, H; Zhang, Y, 2013) |
| "Between 2006 and 2012, a total of 96 esophageal cancer patients (staged cT1N+/T2-4a/N0-3 and M0) were treated according to the above neoadjuvant scheme." | ( Beukema, JC; Bosch, DJ; Burgerhof, JG; Hospers, GA; Muijs, CT; Mul, VE; Plukker, JT, 2014) |
| "In FP chemotherapy for oesophageal cancers, cisplatin-induced nephrotoxicity seems to be unaffected by the SLC22A2 808G>T polymorphism." | ( Hinai, Y; Miura, M; Motoyama, S; Niioka, T, 2013) |
| "A panel of gastric and esophageal cancer cell lines was treated with wortmannin as an Akt-signal inhibitor; the MAPK signal inhibitor PD98059; lapatinib, which inhibits both the epidermal growth factor receptor and HER2 tyrosine kinase; or siRNA for MAPK." | ( Fujii, H; Izawa, S; Kiessling, R; Kono, K; Kua, LF; Mimura, K; Mueller, A; Seliger, B; Shiraishi, K; So, J; Yong, WP, 2013) |
| "We treated 53 thoracic esophageal cancer patients who underwent surgery following neoadjuvant chemotherapy between January 2010 and December 2012." | ( Fujiwara, T; Katsube, R; Maeda, N; Noma, K; Ohara, T; Sakurama, K; Shirakawa, Y; Tanabe, S, 2013) |
| "The study population consisted of 63 esophageal cancer patients treated with neo-CRT." | ( Beukema, J; Hospers, G; Karrenbeld, A; Kluin, P; Langendijk, J; Muijs, C; Mul, V; Plukker, J; Smit, J; van Dam, G, 2014) |
| "However, the number of long-term esophageal cancer survivors has been increasing due to advances in early detection and therapy." | ( Dasanu, CA; Nandy, N, 2014) |
| "We discuss the association between esophageal cancer and subsequent second malignancies, along with implications for surveillance and therapy." | ( Dasanu, CA; Nandy, N, 2014) |
| "Neoadjuvant chemoradiotherapy (CRT) in esophageal cancer (EC) patients may increase the formation of thromboembolic events (TEEs)." | ( Bosch, DJ; Hospers, GA; Mul, VE; Plukker, JT; Van Dalfsen, QA, 2014) |
| "DCF has strong antitumor activity for esophageal cancer and may confer survival benefits when used as preoperative chemotherapy." | ( Baba, H; Baba, Y; Ishimoto, T; Iwagami, S; Iwatsuki, M; Nagai, Y; Watanabe, M; Yoshida, N, 2014) |
| "In 67 patients with advanced esophageal cancer, TF expression in pretreatment biopsy samples was evaluated immunohistochemically and correlated with clinicopathologic factors and response to chemotherapy." | ( Akita, H; Fujiwara, Y; Goto, K; Ishikawa, O; Kishi, K; Marubashi, S; Miyoshi, N; Motoori, M; Noura, S; Ohue, M; Sakon, M; Sugimura, K; Takahashi, H; Tanaka, K; Tomita, Y; Yano, M, 2014) |
| "A database of esophageal cancer was queried for nonmetastatic patients with adenocarcinoma treated between 2000 and 2011 with CRT." | ( Almhanna, K; Freilich, J; Fulp, WJ; Hoffe, SE; Karl, RC; Meredith, K; Shridhar, R; Yue, B, 2014) |
| "In the UK, the standard of care for esophageal cancer has generally combined surgery with neoadjuvant chemotherapy, with definitive chemoradiotherapy (dCRT) being reserved for certain subgroups." | ( Cook, N; Gilligan, D; Hategan, M; Hindmarsh, A; Prewett, S; Qian, W, 2015) |
| "Current treatments for esophageal cancer (EC) rely on tumor eradication by surgery or chemoradiotherapy." | ( Kang, Z; Li, S; Shi, J; Wang, L; Wang, Y; Wen, J; Zhou, Y, 2014) |
| "Patients with a locally advanced esophageal cancer and an homozygous GNAS 393C genotype do not benefit from platinum-based neoadjuvant chemoradiotherapy, indicating that these patients should be treated by alternative treatment strategies." | ( Alakus, H; Bollschweiler, E; Drebber, U; Eberz, PM; Frazer, KA; Harismendy, O; Hölscher, AH; Lowy, AM; Maus, M; Metzger, R; Mönig, SP; Siffert, W; Warnecke-Eberz, U, 2014) |
| "EC‑109 esophageal cancer cells were treated with varying concentrations of compounds 1-7 isolated from the plant as well as the ethanol extract of Artemisia dracunculus." | ( Hong, L; Ying, SH, 2015) |
| "The biomarker TP53 divides esophageal cancer patients into 2 categories with markedly different outcomes: patients with a normal TP53 marker status may experience notable benefits from neoadjuvant chemotherapy with cisplatin/fluorouracil, whereas those with a mutant TP53 marker status appear to be at risk for lack of response." | ( Ba-Ssalamah, A; Hejna, M; Kandioler, D; Kappel, S; Kührer, I; Mittlböck, M; Pluschnig, U; Schoppmann, SF; Wolf, B; Wrba, F; Zacherl, J; Zwrtek, R, 2014) |
| "Twenty patients with esophageal cancer confirmed pathologically were randomly divided into combined treatment (rh-endostatin+DP regimen) group and single chemotherapy group, 10 patients in each group, respectively." | ( Deng, WY; Li, N; Li, X; Luo, SX; Song, T, 2014) |
| "A total of 80 patients with esophageal cancer who underwent radical operations were selected as study patients and randomly divided into an observation group (treated with autologous blood transfusion) and control group (with homologous blood transfusion)." | ( Wang, YC; Xing, YL, 2014) |
| "Patients with esophageal cancer treated with esophagectomy by the same surgeon between 2004 and 2011 were reviewed." | ( Batirel, HF; Bilgi, Z; Celikel, CA; Ermerak, NO; Issaka, A; Kara, VH, 2015) |
| "Ninety oesophageal cancer patients, eligible for high dose (neo-adjuvant) (chemo)radiotherapy, were included." | ( Berveling, MJ; Beukema, JC; Groen, H; Hospers, GA; Langendijk, JA; Muijs, CT; Mul, VE; Plukker, JT; Pruim, J; van der Jagt, EJ; Woutersen, D, 2014) |
| "Neoadjuvant therapy for cancer of the esophagus or gastroesophageal (GE)-junction is well established." | ( Alexandersson von Döbeln, G; Kalman, S; Lund, M; Lundell, L; Nilsson, M; Tsai, JA; Winter, R, 2015) |
| "Patients with stage II, III, or IVA esophageal cancer were randomly allocated to either 2 cycles of ICT (oxaliplatin 130 mg/m(2) on day 1 and S1 at 40 mg/m(2) twice daily on days 1-14, every 3 weeks) followed by concurrent chemoradiotherapy (CCRT) (46 Gy, 2 Gy/d with oxaliplatin 130 mg/m(2) on days 1 and 21 and S1 30 mg/m(2) twice daily, 5 days per week during radiation therapy) and esophagectomy (arm A), or the same CCRT followed by esophagectomy without ICT (arm B)." | ( Cho, KJ; Jang, G; Jung, HY; Kim, HR; Kim, JH; Kim, JY; Kim, SB; Kim, YH; Lee, GH; Ryu, JS; Song, HY; Yoon, DH, 2015) |
| "Thirty-four patients with unresectable esophageal cancer were enrolled and received DNF therapy." | ( Fukuchi, M; Ieta, K; Inose, T; Kato, H; Kuwano, H; Miyazaki, T; Nakajima, M; Ojima, H; Saito, K; Sakai, M; Sano, A; Sohda, M; Suzuki, S; Tanaka, N; Yokobori, T, 2015) |
| "A man in his 60s was diagnosed with esophageal cancer (T3, N0, StageII) and treated with 5-fluorouracil and cisplatin as neoadjuvant chemotherapy (NAC)." | ( Akasaka, H; Hakamada, K; Ichinohe, D; Kimura, A; Kubo, N; Okano, K; Sakuraba, S; Shimada, T; Wajima, N; Yamana, D, 2014) |
| "Forty six patients with esophageal cancer who were treated with concurrent chemo-radiotherapy were enrolled." | ( Lu, WB; Ni, XC; Sun, SP; Sun, ZQ; Wang, J; Wang, JL; Yu, JP, 2015) |
| "Adults with esophageal cancer treated with chemotherapy consisting of 5-fluorouracil and cisplatin and 45-50 Gy radiation were recruited to the study." | ( Bowen, JM; Game, PA; Hussey, DJ; Irvine, T; Karapetis, CS; Keefe, DM; Kristaly, K; Smith, L; Tan, H; Thompson, SK; Tsykin, A; Watson, DI; White, I, 2015) |
| "In the West, where esophageal cancer occurs more frequently than gastric cancer, a phase III trial (the CROSS trial) demonstrated the efficacy of preoperative chemoradiotherapy using carboplatin plus paclitaxel for patients with esophageal or EGJ cancer." | ( Doki, Y; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M, 2015) |
| "Currently, esophageal cancer is rarely curable, and herein, a paclitaxel or 5-fluorouracil/esophageal stent combination (PTX or 5-FU/stent) was used to provide a new approach to treat this cancer." | ( Chen, W; Guo, S; Li, J; Liu, J; Shen, Y; Wang, Z; Wu, K, 2015) |
| "We report a case ofa 60-year old male esophageal cancer patient who was unable to take oral medication, but was successfully treated using a fentanyl citrate buccal tablet." | ( Baba, H; Fujimura, Y; Nakahara, O; Ohshima, S, 2015) |
| "Selected elderly patients with esophageal cancer and adequate functional status should not be excluded from CRT and may be able to tolerate the treatment with acceptable acute toxicities." | ( Bosset, JF; Créhange, G; Guimas, V; Maingon, P; Puyraveau, M; Roullet, B; Servagi-Vernat, S, 2015) |
| "During the treatment of esophageal cancer with curative intent, patients sometimes experience deep vein thrombosis, pulmonary embolism or a central venous catheter-associated thrombus." | ( Kato, F; Kawakubo, H; Kitagawa, Y; Matsuda, S; Omori, T; Takeuchi, H, 2016) |
| "Among 17 patients with advanced esophageal cancer, 2 patients made use of pemetrexed based regimens as first-line treatment,both of them got PR." | ( Huang, XE; Qian, T, 2015) |
| "Our current understanding of oesophageal cancer biology means that personalisation of multimodality therapy is based on accurate clinical staging, allied with patient co morbidities and patient preference." | ( Cosman, P; Das, A; Devadas, M; Lin, M; Merrett, N; Mittal, A; Wilson, R; Ziazaris, W, 2015) |
| "We collected29 advanced esophageal cancer patients who received albumin-bound paclitaxel-based chemotherapy fromJune 2009 to September 2013, and the efficacy and safety of the compound were evaluated." | ( Feng, JE; Mei, JF; Shen, B; Shi, L; Yuan, Y; Zhang, Y, 2015) |
| "Patients diagnosed with esophageal cancer were assessed for treatment response by comparing 2 F-FDG PET/CT scans, at baseline (PET 1) and 1 month after the end of induction chemoradiation (PET 2)." | ( Khong, PL; Tong, DK; Vardhanabhuti, V; Yuan, H, 2015) |
| "We assessed all patients with esophageal cancer of stages I-IV treated with definitive radiotherapy from June 2000 to March 2014." | ( Imae, T; Nakagawa, K; Ohtomo, K; Okuma, K; Omori, M; Takenaka, R; Yamashita, H, 2015) |
| "With the increased incidence of esophageal cancer, chemoradiotherapy continues to play an important role in the management of this disease." | ( Anbalagan, S; Biasoli, D; Hammond, EM; Leszczynska, KB; Mukherjee, S, 2015) |
| "In comparison with HET-1A cells, human esophageal cancer EC109 cells were treated with α-T at corresponding concentrations." | ( Jia, X; Li, Y; Liang, C; Sun, N; Yang, H, 2015) |
| "The survival rate associated with esophageal cancer is very poor due to diagnosis at advanced stages of disease and insensitivity to chemotherapy." | ( Gu, J; Hu, J; Mao, W; Sun, W; Sun, X; Wu, W; Xu, Y; Yu, X; Zhang, G; Zheng, Y, 2015) |
| "Taxane chemotherapy for esophageal cancer causes pneumonitis, not only by itself but also by radiation recall." | ( Endo, M; Fukutomi, A; Hamauchi, S; Kishida, Y; Machida, N; Onozawa, Y; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T, 2018) |
| "We found that hesperetin induced esophageal cancer cells apoptosis in a concentration-dependent and time-dependent manner compared with the untreated cells." | ( Dong, W; Li, J; Liao, F; Wang, J; Wu, D; Zhang, J, 2016) |
| "We report a case of far-advanced esophageal cancer in which induction chemotherapy followed by chemoradiotherapy achieved complete remission." | ( Aga, K; Harada, H; Kaburagi, T; Koizumi, W; Matsumoto, H; Sakata, M; Seki, H; Shimada, A; Watanabe, H; Yasui, N, 2015) |
| "It was diagnosed to as metastatic esophageal cancer and treated with combination chemotherapy consisting of docetaxel (25 mg/m2, days 1, 8, 15) and cisplatin (25 mg/m2, days 1, 8, 15) in a 28-day cycle." | ( Hayashi, T; Horii, N; Inoue, H; Kimura, J; Kunisaki, C; Maezawa, Y; Makino, H; Masuda, M; Ohnishi, H; Ohshima, T; Rino, Y; Suzuki, Y; Takagawa, R; Tsuburaya, A; Yamamoto, J, 2015) |
| "Treatment of esophageal cancer cells with demethylating agent 5-Aza-dC led to increased miR-203a and miR-203b expression, confirming the epigenetic regulation of both miRNAs." | ( Dong, Z; Guo, W; Guo, X; Guo, Y; Kuang, G; Liang, J; Liu, Y; Shen, S, 2016) |
| "Sixty-one patients with advanced esophageal cancer who were scheduled to receive neoadjuvant chemotherapy were randomly allocated to 2 groups." | ( Akita, H; Asahara, T; Fujiwara, Y; Gotoh, K; Ishikawa, O; Kobayashi, S; Miyata, H; Miyoshi, N; Motoori, M; Nomoto, K; Noura, S; Ohue, M; Omori, T; Saito, T; Sakon, M; Sugimura, K; Takahashi, H; Yano, M, 2017) |
| "For these patients with metastatic esophageal cancer, chemotherapy is generally indicated." | ( Hayata, K; Iwahashi, M; Katsuda, M; Matsumura, S; Nakamori, M; Nakamura, M; Ojima, T; Yamaue, H, 2017) |
| "Successful treatment of oesophageal cancer is hampered by recurrent drug resistant disease." | ( Boersma, AW; McKenna, SL; Nyhan, MJ; O'Donovan, TR; Wiemer, EA, 2016) |
| "It is unknown whether restaging oesophageal cancer after neoadjuvant therapy with positron emission tomography-computed tomography (PET-CT) is more sensitive than contrast-enhanced CT for disease progression." | ( Bradley, KM; di Carlo, S; Findlay, JM; Franklin, JM; Gillies, RS; Gleeson, FV; Jones, GE; Maynard, ND; Middleton, MR; Teoh, EJ, 2016) |
| "Information about 406 consecutive esophageal cancer patients with resectable disease who underwent surgery with neoadjuvant chemotherapy consisting of cisplatin plus 5-fluorouracil or who underwent definitive CRT was reviewed." | ( Abe, T; Andoh, M; Kadowaki, S; Kodaira, T; Komori, A; Masuishi, T; Muro, K; Muto, M; Narita, Y; Niwa, Y; Nomura, M; Oze, I; Tachibana, H; Tajika, M; Taniguchi, H; Uemura, N; Ura, T, 2016) |
| "In advanced esophageal cancer patients, standard treatment involves chemoradiotherapy and surgery." | ( Imoto, H; Kiyozaki, H; Obitsu, T; Rikiyama, T; Saito, M; Takata, O; Taniyama, Y, 2016) |
| "The outcomes for patients with esophageal cancer (EC) underwent standard-dose radical radiotherapy were still disappointing." | ( Chang, D; Chen, C; Chen, J; Chen, Z; Guo, H; Guo, L; Huang, R; Li, D; Lin, K; Zhai, T; Zhang, W; Zhou, M, 2016) |
| "In the clinical setting for esophageal cancer, regimens that include nedaplatin might need to be treated as HEC." | ( Aiba, K; Baba, H; Baba, Y; Kitagawa, Y; Miyazaki, T; Nakajima, Y; Shibata, T; Shimada, H; Shimokawa, M; Tsuji, Y; Yamamoto, S; Yoshikawa, T, 2017) |
| "Although standard chemotherapy for esophageal cancer patients is fluorouracil and cisplatin, the prognosis is still unsatisfactory." | ( Matsuhashi, N; Okumura, N; Tanahashi, T; Tanaka, Y; Yamaguchi, K; Yoshida, K, 2016) |
| "In total, 33 patients with recurrent esophageal cancer after initial treatment (esophagectomy, chemotherapy, or chemoradiotherapy) were enrolled." | ( Abe, T; Hazama, S; Kanekiyo, S; Kitahara, M; Michihisa, I; Nagano, H; Nakajima, M; Nishiyama, M; Shindou, Y; Takeda, S; Yoshino, S, 2016) |
| "Patients with resectable oesophageal cancer are treated with neoadjuvant chemoradiotherapy (nCRT) followed by surgery within 3-8 weeks." | ( Creemers, GJ; Kathiravetpillai, N; Koëter, M; Luyer, MD; Nieuwenhuijzen, GA; Rutten, HJ; van der Sangen, MJ, 2016) |
| "Human BE and esophageal cancer cells were analyzed for miR‑193b expression and promoter methylation, with or without treatment with the hypomethylating agent 5‑azacytidine." | ( Chen, J; Gao, J; Gu, X; Liu, T; Lü, L; Mei, Z; Zeng, H, 2016) |
| "FDG-PET/CT images of patients with oesophageal cancer treated with dCRT (from 2003 to 2013) were reviewed to identify the anatomic distribution of FDG-avid LNs." | ( Bennink, RJ; Geijsen, ED; Hulshof, MC; Machiels, M; van Laarhoven, HW; van Os, RM; Wouterse, SJ, 2016) |
| "Forty patients with oesophageal cancer receiving cisplatin-based chemotherapy were assigned to either the ghrelin group (n=20), which received ghrelin (0." | ( Doki, Y; Hosoda, H; Kangawa, K; Kurokawa, Y; Makino, T; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M; Yanagimoto, Y, 2016) |
| "Responses of esophageal cancer to neoadjuvant therapy and patient prognosis are difficult to predict preoperatively." | ( Emi, M; Furukawa, T; Hamai, Y; Hihara, J; Kurokawa, T; Okada, M; Yamakita, I, 2016) |
| "EC109 and TE10 esophageal cancer cells were treated with 0, 10, 20 and 40 mM of PPARg agonist rosiglitazone (RGZ) for 24, 48, and 72 h, and the cell viability and apoptosis were detected using methyl thiazolyl tetrazolium (MTT) assay and Flow cytometric (FCM) analysis, respectively." | ( Liu, D; Qi, Y; Wu, K; Yang, Y; Zhang, C; Zhao, J; Zhao, S, 2016) |
| "A better understanding of how esophageal cancer (EC) cells reactivate primitive signaling to retain glucose metabolism under unfavorable conditions is essential for the development of therapeutic interventions to treat EC." | ( Hochwald, JS; Zhang, J, 2017) |
| "Patients with locally advanced esophageal cancer who are treated with trimodality therapy have a high recurrence rate." | ( Bueno, R; Choi, N; Cleary, JM; Donahue, DM; Enzinger, PC; Fidias, PM; Fuchs, CS; Gaissert, HA; Jaklitsch, MT; Kulke, MH; Lynch, TP; Mamon, HJ; Mentzer, SJ; Meyerhardt, JA; Swanson, RS; Szymonifka, J; Wain, J, 2016) |
| "Patients with stage IIA-IVA esophageal cancer received weekly cisplatin 30 mg/m(2) plus irinotecan 65 mg/m(2) on weeks 1, 2, 4, and 5 concurrently with 5040 cGy of radiation therapy." | ( Bueno, R; Choi, N; Cleary, JM; Donahue, DM; Enzinger, PC; Fidias, PM; Fuchs, CS; Gaissert, HA; Jaklitsch, MT; Kulke, MH; Lynch, TP; Mamon, HJ; Mentzer, SJ; Meyerhardt, JA; Swanson, RS; Szymonifka, J; Wain, J, 2016) |
| "Radiation therapy (RT) for esophageal cancer often results in unintended radiation doses delivered to the heart owing to anatomic proximity." | ( Bennion, NR; Bhirud, AR; Denniston, KA; Gharzai, L; Lin, C; Verma, V, 2016) |
| "Most solid tumours, including oesophageal cancer, contain hypoxic regions that are more resistant to chemoradiotherapy." | ( Berbée, M; Claessens, A; Dubois, LJ; Erdkamp, FL; Lambin, P; Larue, RT; Nap, M; Panth, KM; Peeters, SG; Schreurs, WM; Sosef, MN; Van De Voorde, L; van Elmpt, WJ; Warmerdam, FA, 2016) |
| "For patients with esophageal cancer who received neoadjuvant chemoradiation, pretreatment and posttreatment FDG PET parameters did not correlate with pCR or OS." | ( Arnett, ALH; Haddock, MG; Hallemeier, CL; James, SE; Macintosh, EM; Merrell, KW; Nathan, MA; Neben Wittich, MA; Ravi, K; Shen, KR, 2017) |
| "Twenty esophageal cancer patients receiving chemotherapy with 5-fluorouracil plus cisplatin were assigned randomly to one of the following two groups: (1) receiving elemental diet with Elental (one pack per day) for 14 days and (2) not receiving Elental during chemotherapy." | ( Hoshino, A; Kawada, K; Kawano, T; Miyawaki, Y; Nagai, K; Nakajima, Y; Nishikage, T; Okada, T; Ryotokuji, T; Tokairin, Y, 2017) |
| "Neoadjuvant chemotherapy(NAC)for esophageal cancer is standard in Japan." | ( Katayanagi, S; Kawachi, S; Makuuchi, Y; Osakabe, H; Shigoka, M; Sumi, T, 2016) |
| "50 patients with advanced esophageal cancer were treated with a continuous infusion of CF, 5-FU, and CDDP, and the short-term effects, adverse reactions, and survival periods after treatment were analyzed." | ( Cai, HX; Zhu, ZA; Zhu, ZQ, 2017) |
| "Sixty-five patients with an esophageal cancer treated with a combined chemo-radiation therapy were retrospectively included." | ( Desbordes, P; Di Fiore, F; Gardin, I; Gouel, P; Michel, P; Modzelewski, R; Pineau, P; Ruan, S; Vauclin, S; Vera, P, 2017) |
| "Patients with nonmetastatic esophageal cancer not suitable for surgery can be treated with definitive chemoradiotherapy with curative intent." | ( Fiocco, M; Grootenboers, DA; Marijnen, CA; Neelis, KJ; Peters, FP; Slingerland, M; van Ruler, MA; Vulink, AJ, 2017) |
| "Fifty-seven patients with esophageal cancer invading the trachea/bronchus or aorta who underwent induction therapy followed by surgery were enrolled." | ( Ho, MJ; Kobayashi, S; Miyata, H; Ohue, M; Omori, T; Sakon, M; Sugimura, K; Takahashi, H; Yanagimoto, Y; Yano, M, 2017) |
| "For resectable advanced esophageal cancer, a transthoracic esophagectomy following preoperative treatment is recognized as one of the standard treatments." | ( Fukuda, K; Kawakubo, H; Kitagawa, Y; Matsuda, S; Nakamura, R; Suda, K; Takeuchi, H; Wada, N, 2017) |
| "Long-term outcomes of older esophageal cancer patients (70 y and above) selected for treatment with neoadjuvant chemoradiotherapy followed by surgery or definitive chemoradiotherapy were comparable with the outcomes of their younger counterparts." | ( Aleman, BMP; Grootscholten, C; Sikorska, K; Snaebjornsson, P; van der Kaaij, RT; van Dieren, JM; van Sandick, JW; van Werkhoven, E; Voncken, FEM, 2018) |
| "To diagnose esophageal cancer at an earlier stage, and to improve the effect of anticancer therapy would improve the therapeutic efficacy." | ( Du, N; Li, X; Liang, R; Liu, J; Pang, Y; Ren, H; Sun, X; Tang, SC; Xu, C; Zhang, B; Zhang, J; Zhang, Y, 2017) |
| "After treatment of Eca109/ABCG2 (an esophageal cancer multidrug resistance cell line) cells with adriamycin (ADM) combined with EGCG for 24h, the cellular apoptosis, mitochondrial membrane potential, ADM concentration in cells and ABCG2 protein expression were detected by flow cytometry." | ( Ju, Y; Liu, L; Wang, J; Zhou, R, 2017) |
| "However, its utility in advanced esophageal cancer patients who receive radical esophagectomy with two- or three-field lymph node dissection with perioperative steroid therapy and enhanced recovery after surgery (ERAS) care is unclear." | ( Aoyama, T; Cho, H; Hayashi, T; Kano, K; Maezawa, Y; Masuda, M; Nakajima, T; Ogata, T; Oshima, T; Rino, Y; Sato, T; Yamada, T; Yoshikawa, T, 2017) |
| "A 65-year-old woman ofesophageal cancer received preoperative chemotherapy, and developed EFR before operation." | ( Fujiwara, T; Komoto, S; Maeda, N; Matsumi, Y; Ninomiya, T; Noma, K; Shirakawa, Y; Tanabe, S, 2017) |
| "Researchers often use murine models of esophageal cancer to evaluate novel therapies prior to clinical protocol treatment." | ( Hassan, MS; von Holzen, U, 2018) |
| "Twenty esophageal cancer patients treated with chemoradiation followed by surgery were prospectively enrolled." | ( Carter, BW; Fang, P; Fellman, BM; Hobbs, BP; Lin, SH; Ma, J; Mawlawi, O; Moreno, AC; Musall, BC; Son, JB, 2018) |
| "A total of 105 patients with esophageal cancer will swallowed meglumine diatrizoate and underwent a radiographic examination weekly during radiotherapy, medical personnel observed the esophageal lesions to determine whether an esophageal fistula formed." | ( Du, X; Fan, L; Geng, L; Hu, H; Li, M; Liao, D; Ma, Y; Wu, R; Xiang, M; Zhao, Y; Zhao, Z, 2018) |
| "TJ-100 treatment after esophageal cancer resection has the effects of prompting the recovery of gastrointestinal motility and minimizing body weight loss, and it might suppress the excess inflammatory reaction related to surgery." | ( Fujiwara, S; Furukita, Y; Goto, M; Inoue, S; Minato, T; Miyoshi, T; Nishino, T; Seike, J; Takechi, H; Takizawa, H; Tangoku, A; Toba, H; Yamai, H; Yamamoto, Y; Yoshida, M; Yoshida, T; Yuasa, Y, 2018) |
| "DCF-R treatment for advanced cervical esophageal cancer could be completed by the careful administration; although a strong blood toxicity might occur, this treatment may provide the chance to obtain favorable prognosis with larynx preservation." | ( Heishi, T; Ishida, H; Ito, K; Kamei, T; Konno-Kumagai, T; Maruyama, S; Okamoto, H; Onodera, Y; Sakurai, T; Sato, C; Taniyama, Y; Teshima, J, 2018) |
| "Of 326 patients with esophageal cancer, 189 received GFO administration (GFO group) and 137 did not (control group)." | ( Abe, T; An, B; Higaki, E; Hosoi, T; Kawai, R; Kawakami, J; Saito, T; Shimizu, Y; Uemura, N, 2019) |
| "We evaluated esophageal cancer patients treated between 2006 and 2014 with preoperative IMRT chemoradiation to a dose of 50." | ( Abuodeh, Y; Almhanna, K; Fontaine, JP; Frakes, JM; Hoffe, SE; Meredith, KL; Naghavi, AO; Pimiento, JM; Shridhar, R; Venkat, PS, 2017) |
| "From 2012 to 2016, 26 patients with esophageal cancer underwent pretreatment and intratreatment PET scans during chemoradiotherapy followed by surgery." | ( Ackerson, BG; Cui, Y; Czito, BG; Hong, JC; Marin, D; Palta, M; Rushing, CN; Tandberg, DJ; Willett, CW; Zhang, X, 2018) |
| "The inhibition of esophageal cancer growth by targeting SLC1A5 could, therefore, be used as a preoperative therapy for esophageal cancer." | ( Ca, D; Jiang, N; Lin, J; Pan, Q; Peng, Z; Wu, P; Xiao, H; Yang, T; Zhang, L, 2018) |
| "In patients with esophageal cancer, MTV and TLG derived from pretreatment F-FDG PET are significant prognostic factors." | ( Han, S; Kim, YJ; Lee, JJ; Suh, CH; Woo, S, 2018) |
| "The current treatment approaches for esophageal cancer are associated with poor survival, and there are ongoing efforts to find new and more effective therapeutic strategies." | ( Akhavan Rezayat, K; Avan, A; Fanipakdel, A; Ferns, GA; Gholami, A; Hosseini, S; Javadinia, SA; Joudi Mashhad, M; Taghizadeh Kermani, A; Zardadi, M, 2019) |
| "The proportion of elderly patients in esophageal cancer is now growing, but there is a lack of evidence in term of treatment standard for this group of patients, which is what we aim to obtain through this prospective phase III study." | ( Chang, X; Chen, J; Deng, L; Ge, X; Han, C; Li, C; Liang, J; Lin, Y; Ni, W; Pang, Q; Sun, X; Wang, L; Wang, P; Wang, W; Wang, X; Xiao, Z; Zhang, W; Zhao, Y; Zhou, Z, 2019) |
| "Perforation of esophageal cancer solely due to preoperative chemotherapy is extremely rare, but can be associated with pyothorax and can be difficult to treat." | ( Doki, Y; Kobayashi, T; Makino, T; Mori, M; Tanaka, K; Yamasaki, M, 2019) |
| "The conventional therapy for esophageal cancer is radiotherapy, although its effect is highly limited by the resistance of esophageal cancer cells." | ( Jiao, GH; Qiu, ZH; Zhang, HH; Zhang, WW, 2019) |
| "Among 937 patients with esophageal cancer at Toranomon Hospital between January 2011 and December 2018, 92 who underwent the DCF regimen as initial treatment were selected." | ( Ohkura, Y; Udagawa, H; Ueno, M, 2019) |
| "We report the case of a long-term esophageal cancer survivor treated by esophageal bypass operation for ERF after chemoradiotherapy (CRT)." | ( Emi, M; Hamai, Y; Ibuki, Y; Miyata, Y; Ohsawa, M; Okada, M, 2019) |
| "Dysphagia is a major symptom of esophageal cancer (EC) that significantly affects patient quality of life; however, little is known regarding its clinical impact on the treatment course in patients with EC." | ( Doki, Y; Hagi, T; Kimura, Y; Makino, T; Mori, M; Motoori, M; Nishida, N; Sakai, D; Satoh, T; Tanaka, K; Yamasaki, M, 2019) |
| "Background Esophageal cancer is a very common malignant tumor in China, especially esophageal squamous cell carcinoma (ESCC), but there is currently no effective treatment for patients after first-line chemotherapy failure." | ( Lei, J; Song, X; Wang, Y; Yu, J; Zhang, C; Zhang, N; Zhang, S; Zhao, J, 2020) |
| "for this purpose, Esophageal cancer cell (YM1) derived spheres were treated in vitro with OPE, NR, Dox, Dox in combination with OPE or NR." | ( Asadi, J; Ghasemnejad, A; Khosravi, A; Samadi, F; Tajaldini, M, 2020) |
| "Locally advanced esophageal cancer (EC) invading surrounding organs (T4b) is difficult to treat." | ( Fujiwara, T; Hashimoto, M; Katsui, K; Maeda, N; Nishizaki, M; Noma, K; Sakurama, K; Shirakawa, Y; Tanabe, S, 2020) |
| "The optimal dose in esophageal cancer patients treated with definitive chemoradiation (CRT) remains debated." | ( Carrère, N; Dalmasso, C; Guimbaud, R; Izar, F; Lusque, A; Modesto, A; Moyal, E; Rives, M; Vieillevigne, L, 2020) |
| "Patients with esophageal cancer treated with dCRT between January 2004 and November 2016 were included in this retrospective analysis." | ( Ishikura, S; Kondo, T; Miyakawa, A; Murai, T; Ozawa, Y; Shibamoto, Y; Sugie, C; Yanagi, T, 2020) |
| "Chemotherapy resistance of esophageal cancer is a key factor affecting the postoperative treatment of esophageal cancer." | ( Huang, X; Ma, X; Shi, S; Zhang, Q; Zhu, X, 2020) |
| "Among patients with esophageal cancer who received treatment with curative intention, cisplatin-fluorouracil was associated with better survival compared to carboplatin-fluorouracil, while patients with gastroesophageal junction cancer who were treated with cisplatin-fluorouracil had worse survival compared to fluorouracil-oxaliplatin." | ( Ebrahim, F; Ekheden, I; Henriksson, R; Ólafsdóttir, H; Raaschou, P; Wettermark, B; Ye, W, 2020) |
| "Patients with oesophageal cancer undergoing neoadjuvant chemoradiotherapy and surgery are at substantial risk of thromboembolic and bleeding events throughout all stages of treatment." | ( Büller, HR; Hovenkamp, A; Hulshof, MCCM; Kamphuisen, PW; Middeldorp, S; Mulder, FI; van Berge Henegouwen, MI; van Es, N; van Laarhoven, HWM, 2020) |
| "Unresectable esophageal cancer harbors high mortality despite chemoradiotherapy." | ( Chang, YC; Chao, YK; Chen, PJ; Ho, AT; Hsieh, JC; Hung, TM; Lee, CH; Pai, PC; Tseng, CK; Yang, CK; Yap, WK, 2020) |
| "The patient was a 71-year-old man with esophageal cancer who was referred to the oncology outpatient clinic for evaluation to determine the treatment plan." | ( Ishida, M; Onishi, H; Sato, I; Yoshioka, A, 2021) |
| "Patients with locally advanced oesophageal cancer who were treated with nCRT and oesophagectomy from July 2010 to February 2017 were analysed." | ( Ahn, MJ; Choi, JY; Lee, J; Lim, SW; Oh, D; Park, K; Shim, YM; Sun, JM; Zo, JI, 2020) |
| "Patients diagnosed with resectable oesophageal cancer who underwent neoadjuvant therapy should not be exempt from surgery based on PET-CT results." | ( Ahn, MJ; Choi, JY; Lee, J; Lim, SW; Oh, D; Park, K; Shim, YM; Sun, JM; Zo, JI, 2020) |
| "Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy." | ( Adenis, A; Al-Rajabi, R; Bennouna, J; Bhagia, P; Chen, J; de la Fouchardiere, C; Doi, T; Enzinger, P; Ferreira, P; Francois, E; Girotto, G; Hsu, CH; Kang, SP; Kato, K; Kim, SB; Kojima, T; Lee, SH; Lordick, F; Metges, JP; Moriwaki, T; Muro, K; Qin, SK; Senellart, H; Shah, MA; Shen, L; Suryawanshi, S; Wang, R, 2020) |
| "There were 291 esophageal cancer patients who received neoadjuvant/definitive chemoradiation therapy." | ( Farrugia, MK; Flaherty, L; Ma, SJ; Mattson, DM; Repasky, EA; Singh, AK, 2020) |
| "EGFR CNG in gastroesophageal cancer patients was associated with improved overall survival following fluoropyrimidine/platinum chemotherapy." | ( Baxter, M; Challapalli, P; Clark, C; Collinson, D; Iannetta, J; Meemanage, M; Miedzybrodzka, Z; Murray, G; Petty, RD; Spender, LC; Turbitt, J; Walsh, S, 2021) |
| "Definitive chemoradiotherapy(CRT)for esophageal cancer is the standard treatment and alternative to surgery." | ( Asagi, A; Hamamoto, Y; Hasebe, A; Hino, K; Hori, S; Inoue, T; Kajiwara, T; Kataoka, M; Nadano, S; Nakasya, A; Nishide, N; Nishina, T; Sakaguchi, C; Tanimizu, M; Terao, T; Yoshimatsu, M, 2020) |
| "A cohort of 113 patients with esophageal cancer who performed 18F-FDG PET/CT preneoadjuvant therapy was assessed." | ( Albenda, DG; Buchpiguel, CA; Cecconello, I; Duarte, PS; Junior, UR; Sallum, RAA; Takeda, FR; Tustumi, F, 2021) |
| "In patients with advanced esophageal cancer, PET/CT has a significant impact on clinical management by improving the selection of individualized treatment strategies and avoiding additional diagnostic procedures." | ( Gani, C; Gatidis, S; la Fougère, C; Nikolaou, K; Pfannenberg, C; Reinert, CP; Sekler, J, 2021) |
| "Gastro-oesophageal cancers (GEC) are resistant to therapy and lead to poor prognosis." | ( Ajani, JA; Bhutani, M; Chen, Q; Correa, A; Estrella, JS; Gan, B; Hofstetter, WL; Huo, L; Jin, J; Johnson, RL; Lee, JH; Lei, G; Li, CY; Li, Y; Liu, B; Ma, L; Pizzi, MP; Scott, A; Shanbhag, N; Song, S; Wang, Y; Wei, S; Weston, B; Xiao, L, 2021) |
| "Patients with proximal esophageal cancer treated with CRT between 2004 and 2014 in 11 centers in the Netherlands were included." | ( Blom, GJ; Bogers, JA; Bouwense, SAW; Braam, PM; de Jong, MA; de Vos-Geelen, J; Geurts, SME; Hoebers, FJP; Jeene, PM; Kasperts, N; Muijs, CT; Nieuwenhuijzen, GAP; Rozema, T; Tjan-Heijnen, VCG; Valkenburg-van Iersel, LBJ; Voncken, FEM, 2021) |
| "To compare the chemoradiotherapy for esophageal cancer followed by surgery study (CROSS) and continuous infusion 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) protocols administered in distal esophageal and gastroesophageal junction (GEJ) tumors in terms of effectiveness and toxicity." | ( Ates, O; Cakmak Oksuzoglu, OB; Karadag, I; Karakaya, S, 2021) |
| "The human oesophageal cancer cell line TE-1 was treated with the combination of EPA and CDDP." | ( Higashida, M; Hirai, T; Kubota, H; Matsumoto, H; Miyake, S; Ogo, A; Teramoto, F; Ueno, T, 2021) |
| "Chemoradiotherapy for Esophageal cancer followed by Surgery (CROSS regimen) is standard of care for locally-advanced esophageal cancer." | ( Cooper, L; De León, LE; Dezube, AR; Dumontier, C; Enzinger, P; Frain, LN; Jaklitsch, MT; Kucukak, S; Mamon, H; Mazzola, E; Wee, JO, 2021) |
| "Human esophageal cancer cell line Eca109 was treated with 5 μg/mL or 10 μg/mL of quercetin." | ( Cheng, D; Li, CL; Liu, KD; Liu, Y; Sun, ZQ; Xu, QQ, 2021) |
| "In this study, we treated esophageal cancer (EC) cell lines, TE1 and KYSE450 with coptisine (COP) and investigated the biological effects of COP in EC cells." | ( Chen, X; Liu, C; Qu, S; Wen, X; Yang, Y; Zhang, X, 2021) |
| "We reviewed 52 patients with esophageal cancer who were treated with the first tPDT at Kyoto University Hospital between October 2015 and April 2020." | ( Amanuma, Y; Higuchi, H; Hirohashi, K; Horimatsu, T; Mitani, Y; Muto, M; Ohashi, S; Tamaoki, M; Yokoyama, A; Yoshioka, M, 2021) |
| "The Neoadjuvant Chemoradiotherapy for Esophageal Cancer 5010 study was a multicenter open-label randomized phase 3 clinical trial that enrolled patients between June 1, 2007, and December 31, 2014." | ( Chen, B; Chen, Y; Chen, Z; Fang, W; Fu, J; Guo, X; Han, Y; Kong, M; Li, Q; Li, T; Lin, T; Liu, H; Liu, M; Mao, T; Mao, W; Pang, Q; Wang, G; Wang, J; Xiang, J; Yang, H; Yu, Z; Zhang, X; Zheng, X; Zhu, C, 2021) |
| "First-line therapy for advanced oesophageal cancer is currently limited to fluoropyrimidine plus platinum-based chemotherapy." | ( Adenis, A; Antunes, L; Bhagia, P; Cho, BC; Doi, T; Enzinger, P; Fountzilas, C; Goekkurt, E; Hara, H; Kato, K; Kim, SB; Kojima, T; Li, SH; Li, Z; Liu, Q; Mansoor, W; Maqueda, MA; Metges, JP; Oliden, VC; Shah, MA; Shah, S; Shen, L; Sun, JM; Sunpaweravong, P; Tsuji, A, 2021) |
| "Although cure rates in esophageal cancer (EC) have improved since the introduction of neoadjuvant chemoradiation (nCRT), evidence for treatment-related cardiac toxicity is growing, of which the exact mechanisms remain unknown." | ( Beukema, JC; de Groot, C; Langendijk, JA; Muijs, CT; Plukker, JTM; Prakken, NHJ; van Luijk, P; van Melle, JP; Vliegenthart, R, 2022) |
| "In preoperative chemotherapy for esophageal cancer, the incidence of hematological toxicity was significantly higher in patients with low skeletal muscle mass." | ( Fujii, H; Hatanaka, Y; Imai, T; Mase, J; Matsuhashi, N; Ojio, H; Okumura, N; Sato, Y; Suetsugu, T; Takahashi, T; Tanaka, Y; Yoshida, K, 2022) |
| "Here, we present a case of esophageal cancer that was treated with esophagectomy, chemotherapy, and radiation therapy and developed oligometastases of the foot after 8 years in remission." | ( Dadparvar, S; Posocco, D; Ricely, JM, 2022) |
| "Fifty-one patients with esophageal cancer treated with radiation who underwent pre- and post-treatment FDG-PET scans were retrospectively evaluated." | ( Castillo, E; Castillo, R; Goodman, KA; Jones, B; Miften, M; Olsen, J; Schefter, T; Vinogradskiy, Y; Zakem, SJ, 2023) |
| "For FDG PET/CT and CT undetectable esophageal cancer, incorporation of the endoscopic measurement with PET/CT might be a way for making radiotherapy plan." | ( Chang, JS; Chang, WL; Chiu, NT; Hsu, SW; Lin, FC, 2022) |
| "The standard of treatment for esophageal cancer with adjacent organ invasion (T4) has not been established." | ( Aoshika, T; Iino, M; Kamada, T; Kano, K; Katoh, H; Mizoguchi, N; Saito, S; Shima, S; Takakusagi, Y; Taniuchi, R; Tsuchida, K; Yoshida, D, 2022) |
| "Patients with esophageal cancer can develop distant metastases between the start of neoadjuvant chemoradiotherapy (nCRT) and planned surgery (ie, interval distant metastases)." | ( Bakker, AS; Haj Mohammad, N; Jairam, J; Kroese, TE; Meijer, GJ; Mook, S; Ruurda, JP; van der Horst, S; van Hillegersberg, R; van Rossum, PSN, 2022) |
| "However, patients with esophageal cancer and PD-L1 CPS ≥ 10 may gain the most LYs from initial PPF treatment." | ( Ding, D; Liu, K; Peng, L; Zhou, Y; Zhu, Y, 2022) |
| "In open esophagectomy for esophageal cancer, steroid administration is associated with attenuated postoperative inflammation and reduced complications." | ( Daiko, H; Fujii, Y; Ishiyama, K; Kanematsu, K; Kubo, K; Kurita, D; Oguma, J, 2022) |
| "Forty treatment-naive esophageal cancer patients were recruited and divided into two groups: the ICG and control groups." | ( Chen, C; Du, J; Xu, G; Yang, Z; Zheng, B, 2022) |
| "The 49-year male with oesophageal cancer presented with haematemesis and had received neo-adjuvant chemotherapy 3 weeks back." | ( Iftikhar, J; Saqib, M; Siddique, MZ; Yusuf, MA, 2022) |
| "The 70 esophageal cancer patients were divided into radiotherapy-sensitive and radiotherapy-insensitive groups according to the efficacy of radiotherapy, and the methylation status of DACH1 was compared between the two groups." | ( Gu, Z; Huang, J; Jiang, L; Wang, W; Xu, Y; Zhu, W, 2022) |
| "Surgery is the treatment of choice for esophageal cancer." | ( Kim, MJ; Lee, JE, 2022) |
| "As the preoperative examination of esophageal cancer has improved, the likelihood of finding diseases in other organs that require surgical treatment has also increased." | ( Huang, C; Li, K; Li, X; Liu, X; Sun, S; Wang, Z; Zhang, G, 2023) |
| "To test this hypothesis, we treated esophageal cancer cells with CAP while controlling the supply of glutamine." | ( Jing, X; Wang, T; Zhang, F; Zhao, W, 2023) |
| "In patients with esophageal cancer, muscle loss induced by neoadjuvant therapy before esophagectomy is correlated with poor prognosis." | ( Ebata, T; Fukaya, M; Miyata, K; Shimizu, D; Sugita, S, 2023) |
| "Patients with esophageal cancer who underwent neoadjuvant therapy before esophagectomy between 2009 and 2020 were investigated (n=132)." | ( Ebata, T; Fukaya, M; Miyata, K; Shimizu, D; Sugita, S, 2023) |
| "Additionally, human esophageal cancer cells were treated with formononetin, and the effects on the proliferation and cell cycle of esophageal cancer cells were assessed by the CCK-8 assay and flow cytometry." | ( Chen, L; Guo, LR; Jin, J; Li, S; Xing, D, 2023) |
| "Interestingly, patients with gastroesophageal cancer benefitted more from this therapy." | ( Brossart, P; Feldmann, G; Gonzalez-Carmona, MA; Jafari, A; Kalff, JC; Köksal, M; Lingohr, P; Mahn, R; Mańczak, A; Möhring, C; Monin, MB; Sadeghlar, F; Sarria, GR; Sommer, N; Strassburg, CP; Timotheou, A; Toma, M; Zhou, T, 2023) |
| "We report a case of esophageal cancer with consciousness disorder due to hyperammonemia during FP treatment with an examination of some of the relevant literature." | ( Chiba, T; Hayashi, M; Iseki, H; Matsui, T; Miura, T; Noguchi, N; Ryotokuji, T; Tsunemi, A; Yamasaki, Y; Yokosuka, T, 2023) |
| "Patients with advanced esophageal cancer carry poor prognoses; limited data exist to guide second-line therapy in the metastatic setting." | ( Benson, A; Burtness, BA; Catalano, P; Cohen, SJ; Crandall, TL; Dotan, E; Fisher, GA; Kumar, P; Lubner, SJ; Mitchell, EP; Mulcahy, MF; Stockton, S, 2023) |
| "Detection of residual oesophageal cancer after neoadjuvant chemoradiotherapy (nCRT) is important to guide treatment decisions regarding standard oesophagectomy or active surveillance." | ( Bennink, RJ; Beukinga, RJ; Chatterjee, A; Doukas, M; Lagarde, SM; Lambin, P; Noordzij, W; Plukker, JTM; Roef, MJ; Schreurs, W; Valkema, MJ; Valkema, R; van Klaveren, D; van Lanschot, JJB; Wijnhoven, BPL; Woodruff, HC, 2023) |
| "In patients with inoperable esophageal cancer receiving concurrent systemic therapy, adding liquid nitrogen spray cryotherapy was safe and associated with improvement in dysphagia and QoL without causing reflux." | ( Garcia, R; Gupta, D; Gupta, S; Jewett, E; Kachaamy, T; Kaul, V; Mohapatra, S; Munsey, R; Pannala, R; Pollard, K; Rojas-DeLeon, M; Shah, T; Sharma, N; Vashi, P; Zelt, C, 2023) |
| "We treated two human esophageal cancer cell lines, KYSE30 and KYSE960, with up to 10 µg/mL of propofol for 12-36 h." | ( Konishi, Y; Nishiwaki, K; Zhang, A; Zhou, R, 2023) |
| "Despite recent advances in the study of esophageal cancer, there has been only limited improvement in the treatment and prognosis." | ( Gao, Y; Sheng, G; Wang, T; Wu, H; Wu, J, 2023) |